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ALCL   anaplastic large cell lymphoma 
APC   antigen presenting cell 
APRIL   A proliferation-inducing ligand 
ATCC   American Type Culture Collection 
ATL   adult T-cell leukemia 
Apc   allophycocyanin 
bp   base pair 
BAT3   HLA-B-associated transcript 3 
BAFF   B-cell activating factor 
BCMA  B-cell maturation antigen 
BSA   bovine serum albumin 
CCL   chemokine (c-c motif) ligand 
CD   cluster of differentiation 
CFSE   carboxy fluorescein diacetate succinimidyl ester 
cDNA   complementary DNA 
DCFHDA  2’,7’-Dichlorofluorescein diacetate   
DNA   deoxy ribonucleic acid 
EBV   Epstein-Barr virus 
ELISA   enzyme-linked immunosorbent assay 
ERK   extracellular-regulated kinase 
FACS   fluorescence-activated cell sorting 
FADD   Fas-associated protein death domain 
FITC   fluorescein isothiocyanate 
GAPDH  glycerolaldehyde-3-phosphate dehydrogenase 
GMCSF  granulocyte macrophage colony stimulating factor 
X g   relative centrifugal force 
GST   glutathione S-transferase 
HIV   human immunodeficiency virus 
Abbreviations 
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HL   Hodgkin Lymphoma 
HRP   horseradish peroxidase 
HTLV   human T-lymphotropic virus 
IMDM   Iscove’s modified Dulbecco’s medium 
IL   interleukin 
IS   immunological synapse 
IFN   interferon 
iDC   immature dendritic cells 
JNK   c-Jun-n-terminal kinase 
kDa   kilo Dalton 
LPS   lipopolysaccharide 
MAPK   mitogen-activated protein kinase  
MAb   monoclonal antibody 
MFI   mean fluorescence intensity 
Mo-iDC  monocyte-derived immature dendritic cells 
MOPS   3-N-morpholino propane sulfonic acid 
NK   natural killer 
NF-B   nuclear factor kappa-light –chain-enhancer of activated B cells 
O.D   optical density 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PE   phycoerythrin 
PerCP   peridinin-chlorophyll protein 
pH   negative log of hydrogen ion concentration 
PHA   phyto-hemagglutinin 
PVA   polyvinylalcohol 
RA   rheumatoid arthritis 
ROS   reactive oxygen species 
RT   room temperature 
RPM   rotations per minute 
sCD30   soluble CD30 
Abbreviations 
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SLE   systemic lupus erythematosus 
TACI transmembrane activator and calcium-modulator and cytophilin ligand 
TBS   tris-buffered saline 
TLR   toll-like receptor 
TNF   tumor necrosis factor 
TNFR   tumor necrosis factor receptor 
TRADD  TNF receptor death domain 
TWEAK  TNF-like weak inducer of apoptosis 
VEGI   vascular endothelial cell-derived growth inhibitor 
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 Zusammenfassung 
Der CD30 Rezeptor und der korrespondierende Ligand (CD30L) sind membranständige 
Glykoproteine der tumor necrosis factor receptor (TNFR) beziehungsweise der tumor necrosis factor 
receptor ligand Superfamilie. CD30 wurde ursprünglich als lymphoid activation antigen (Ki-1) in 
Hodgkin Lymphom (HL) Patienten identifiziert. Der Serumspiegel des löslichen Rezeptors, der von 
der Zelloberfläche nach proteolytischer Spaltung freigesetzt wird, gilt als prognostischer Marker bei 
Patienten mit HL. Die Rolle der CD30-CD30L Interaktion für inflammatorische Prozesse ist in 
verschiedenen Modellen beobachtet worden, wobei die molekularen Grundlagen vielfach noch nicht 
gut verstanden sind. So sind Daten zur Expression und Funktion von CD3
0/CD30L auf Zellen des angeborenen Immunsystems wie Granulozyten, Natürlichen Killer (NK)-
Zellen und dendritischen Zellen unvollständig und zum Teil widersprüchlich.  
Im Rahmen dieser Arbeit wird gezeigt, dass unreife dendritische Zellen (iDCs) und Granulozyten 
CD30L exprimieren. Die Aktivierung von CD30L auf iDCs mit immobilisiertem CD30 Rezeptor führt 
zur Reifung der iDCs und zur Sekretion pro-inflammatorischer Zytokine. CD30-stimulierte DCs sind 
wie professionelle antigenpräsentierende Zellen in der Lage, eine Polarisation und Proliferation von 
T-Zellen auszulösen. Es wurde nachgewiesen, dass die Aktivierung von CD30L zur Bildung reaktiver 
Sauerstoffspezies führt (ROS) und den MAP-Kinase Signalweg und die Zytokin-Ausschüttung 
aktiviert. 
Die Reifung von NK Zellen und iDCs in der frühen Phase der Immunantwort beruht auf der 
gegenseitigen Aktivierung beider Zelltypen. In diesem Zusammenhang wurde gezeigt, dass CD30 
Rezeptor exprimierende NK Zellen die Reifung von iDCS in einer CD30-CD30L abhängigen Weise 
unterstützen. Somit könnten CD30-positive NK Zellen für die CD30L-vermittelte Reifung von iDCs 
in der frühen Phase der Immunantwort verantwortlich sein. Der lösliche CD30 Rezeptor stimuliert im 
Gegensatz zum membranständigen oder zum immobilisierten Rezeptor die Reifung von iDCs nicht. 
Werden jedoch CD30L-exprimierende Granulozyten mit dem löslichen CD30 Rezeptor inkubiert, so 
führt dies zur Aktivierung ihrer Migration und zur Sekretion des pro-angionetischen Faktors IL-8.  
Die Daten belegen, dass CD30 und CD30L wichtige immun-regulatorische Faktoren für Immunzellen 
des angeborenen Immunsystems sind. So wird diskutiert, dass die Zell-Zell Kontakt vermittelte CD30-
CD30L Interaktion die akute inflammatorische Immunantwort über die Steuerung der NK-DC 
Kommunikation beeinflusst. Der lösliche CD30 Rezeptor spielt hingegen eher bei der chronischen 
Entzündung über die Mobilisierung von Granulozyten und die IL-8 Sekretion eine wichtige Rolle.
Abstract 
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CD30 and CD30 ligand (CD30L) are cell surface glycoproteins of the tumor necrosis factor receptor 
(TNFR) and the tumor necrosis factor receptor ligand super-family, respectively. CD30 was originally 
identified as the lymphoid activation antigen (Ki-1) in Hodgkin Lymphoma (HL) patients and the 
serum level of the soluble shed receptor is considered as a prognostic marker. The role of the CD30-
CD30L interaction for inflammatory processes has been observed in several models. However, the 
participating cells and the molecular mechanisms of the cross-talk are not well understood. In 
particular, data on the expression and function of both membrane proteins in innate immune cells such 
as granulocytes, natural killer (NK) cells and dendritic cells (DCs) are incomplete and discussed 
controversially.  
This study demonstrates that immature DCs (iDCs) and granulocytes express CD30L. Moreover, the 
physiological function of CD30L on iDCs is shown: in vitro the engagement of the membrane-
anchored molecule using immobilized CD30 caused reverse signaling leading to iDC maturation. The 
CD30-maturated DCs were functional, since they were able to directly cause polarization and 
proliferation of allogenic T cells. Furthermore, the engagement of CD30L induced the generation of 
reactive oxygen species (ROS) and activation of the MAP-kinase pathway in iDCs, consequently 
leading to a specific release of pro-inflammatory cytokines.  
The stimulation of NK cells and iDCs in the early phase of an immune response is dependent on the 
reciprocal activation of both cell types. Here, it was demonstrated that activated CD30 receptor-
expressing NK cells promoted iDC maturation and this was inhibited upon abrogation of the CD30-
CD30L interaction. Thus, CD30-positive NK cells might be the cell type that engages CD30L on 
iDCs to initiate the immune response. In contrast, stimulation of iDCs with soluble CD30 (sCD30) did 
not promote iDC maturation but induced the release of the anti-proinflammatory cytokine IL-10. 
Interestingly, sCD30 triggers also the migration capacity of CD30L-expressing granulocytes and the 
release of IL-8. This indicates a broader immunomodulatory effect and suggests a pro-angiogeneic 
role for sCD30. 
In conclusion, both membrane-anchored CD30 and sCD30 are effective immune regulators. Whereas 
cell contact-dependent CD30-CD30L interaction might support acute inflammation through NK-DC 
cross-talk, sCD30 rather plays a role in chronic inflammation through IL-8 release and mobilization of 
granulocytes. 
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The immune system protects against diseases by identifying and eliminating pathogens and 
suppressing the growth of tumor cells. The functions are achieved by two parts, the so called 
innate immunity and adaptive immunity. The innate immune system consists of molecules 
and cells that distinguish host cells from infected ones, in part by recognizing conserved 
constituents of microorganisms and it is activated within hours. The efficacy of primary 
immune response is not significantly increased by previous exposure. In contrast, the 
lymphocytes of the adaptive immune system, and the antibodies they produce, can recognize 
essentially an unlimited number of different targets but become effective only after a delay of 
two to four days on first encounter with a given microorganism. 
 The communication between innate and adaptive immune cells is responsible for the 
generation of an adequate immune response. This communication is dependent on cell-cell 
contacts and soluble factors. Many of the effective cytokines and their receptors belong to the 
Tumor Necrosis Factor (TNF) and Tumor Necrosis Factor Receptor (TNFR) super-families, 
respectively. 
 	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O’Malley and coworkers showed that the effects of tumor inflammation due to 
bacterial lipopolysaccharide (LPS) is dependent on a soluble factor in the serum, which was 
termed  tumor-necrotizing factor and renamed by L. Old’s group as tumor necrosis factor 
(TNF) (Carswell et al. 1975). Later, a second molecule was discovered as lymphotoxin (LT), 
a protein that is produced by lymphocytes and kills tumor cells (Williams and Granger 1968). 
Then, the cDNAs for LT and TNF were isolated and their protein sequence was deciphered 
(Gray et al. 1984; Pennica et al. 1984). The sequence homology between these two proteins 
(30% amino acid identity) and the existence of common cell surface receptors led to the 
renaming of TNF and LT to TNF-alpha and TNF-beta, respectively. These two cytokines 
(TNF-alpha and TNF-beta) were the first members of a family of cytokines, now known as 
TNF super-family. Considerable advances have been made during past two decades in 
understanding the biology and the clinical role of the TNF super-family. 
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Tumor necrosis factors and its receptors are structurally related to an increasing 
number of molecules, therefore belonging to two super-families: the above mentioned TNF 
super-family (TNF-SF) and the TNF receptor super-family (TNFR-SF). To date, 19 different 
ligands and 32 receptors have been identified. Although the majority of the TNF family 
members consist of ligand/receptor pairs, some ligands have more than one receptor, and 
some receptors are shared between more than one ligand. These receptor-ligand pairs of 
molecules play diverse roles in inflammation, in the immune response, in organogenesis of 
lymphoid and bone tissues and other body structures, and in apoptosis (Locksley et al. 2001; 
Croft 2003).  
Identification of these structurally related proteins was performed by large-scale 
sequencing of “expressed sequenced tags” (ESTs) (Smith et al. 1994). Unlike TNF-alpha and 
LT, the ligands for receptors Fas (CD95), CD27, CD30, CD40, 4-1BB, OX40 and herpes-
virus entry mediator (HVEM) were identified by direct expression-cloning strategies 
(Yonehara et al. 1989; Itoh et al. 1991; Smith et al. 1994; Locksley et al. 2001). The 
description of the amino acid sequences of several ligands and receptors of the super-family 
led to the identification of certain regions of homology. Instead of an expression-cloning 
strategy, the availability of human genome sequences also led scientists to use homology 
searches to identify several additional members of the TNF super- family. TNF-related 
apoptosis-inducing ligand (TRAIL) (Wiley et al. 1995), followed by the identification of 
receptor activator of nuclear factor-B (NF-B) ligand (RANKL), also known as TRANCE 
(TNF-related activation-induced cytokine) or OPGL (osteoprotegenin ligand) has pronounced 
a major advancement in the understanding of apoptosis (Anderson et al. 1997; Wong et al. 
1997; Lacey et al. 1998). 
Most of the TNF family ligands are mainly expressed by Antigen Presenting Cells 
(APCs) including B cells, T cells, NK cells, dendritic cells, granulocytes and monocytes 
(Aggarwal 2003). CD70 is mainly expressed by B cells (Hintzen et al. 1994), whereas 
OX40L, 4-1BBL and CD30L are more often expressed by broad range of professional APCs. 
By contrast, LIGHT is expressed by iDCs, with no reports of B-cell expression and is down-
regulated during the process of maturation (Tamada et al. 2000). The expression of these 
Introduction 
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ligands can be induced individually by various factors like CD40, LPS or B-cell receptor and 
cause activation/maturation of APCs (Pollok et al. 1994; Ohshima et al. 1997). 
The biologically active forms of TNF ligands and receptors are self-assembled trimer 
molecules. The trimers do not share any sequence homology at receptor-binding site, but they 
do share 25-30 sequence homologies at tri-merization sites. The ligands are either type-11 
trans-membrane proteins (N-terminal inside the cell and C-terminal outside the cell) or 
soluble forms (Kwon et al. 1999). Similarly, the receptors can exist in either trans-membrane 
(Type 1) or soluble forms. 
The functional outcome of the interactions between TNF/TNFR-SF members has been 
consistent with the notion that most of the TNF molecules receive and deliver signals upon 
specific interaction with their receptors. Two possible mechanisms might lead to the specific 
function: (i) direct cell-to-cell contact and (ii) soluble factor-dependent interaction with 
receptors. In general, most of the TNF family proteins are expressed in soluble form or 
released from the cell surface due to the cleavage through specific metalloproteases. The 
function of most ligands has been widely investigated. An intriguing feature of these ligands 
is that when certain ligands are shed, they inhibit the function of ligand-receptor complex. For 
example, membrane–bound CD95 ligand (CD95L) kills human peripheral blood T cells, 
soluble CD95L blocks this killing (Suda et al. 1997). The fact that some soluble ligands act as 
agonists and others as antagonists is still not solved on the molecular level. 
Members of the TNF super-family proteins have versatile functions during the 
immune response. The outcome of the interaction is apoptosis (TNF, LT, TRAIL, VEGI, 
TWEAK and LIGHT), survival (RANKL and BAFF), differentiation (TNF, RANKL and 
DR6) or proliferation (TNF, CD27L, CD30L, CD40L, OX40L, 4-1BBL, APRIL and BAFF).  
The activation pathways involve NK-B, c-Jun N-terminal kinase (JNK), p42/p44 and p38 
MAPK. Additionally, the co-stimulatory TNFR-TNF family members like, OX40-OX40L 
(CD134), 4-1 BB (CD137)-4-1BBL, CD27-CD70, CD30-CD30L (CD153), CD40-CD40L 
(CD154) and HVEM (herpes-virus entry mediator)-LIGHT play a major role as positive 
regulators of T-cell function (Fig. 1). 
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Figure 1: Structural Organisation of the co-stimulatory TNFR/TNF-family members 
The tumor necrosis factor (TNF) receptor ligands (top) are shown as homotrimeric type II transmembrane 
proteins. The TNF receptor (TNFR) family molecules (bottom) are depicted as type I transmembrane monomers 
that are thought to associate in trimers when interacting with their ligands. The total amino acid length and 
number of intra-cellular amino acids (parantheses) are indicated. 
 
 
 
 
Croft, 2003 
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CD30 and CD30L are one of the major receptor-ligand pairs of TNFR/TNF-SF proteins 
involved in inflammatory responses. Several reports describe that CD30L activates and 
stimulates CD30 to induce NF-B pathway leading to cell survival.  Apart from the basic 
stimulatory function on CD30, CD30L has another characteristic feature in the inflammatory 
immune response by increasing the cytokine pool that is responsible for leukocyte migration 
(IL-8 release from granulocytes) (Wiley et al. 1996). The above two functions, combined 
with the published data concerning other ligands in the TNF family (Stuber et al. 1995; van 
Essen et al. 1995) suggest that TNF family members and their cognate receptors signal bi-
directionally. 
 	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CD30 is a type I trans-membrane glycosylated protein of 105 to 120 kDa. The proteomic 
analysis of human CD30 demonstrates that this molecule has an 18-residue leader peptide, 
followed by a 362 amino acid extra-cytoplasmic domain, a 24-amino acid trans-membrane 
region, and a cytoplasmic domain of 188 amino acids. By contrast, murine and rat CD30 have 
498 and 493 amino acids, respectively (Fig. 2). The extra-cellular domain of human CD30 
has six cysteine-rich regions in a duplicated structure (Durkop et al. 1992), whereas murine 
and rat lack the second cluster. This region shows significant homology to those of other 
TNFR super-family members. The human CD30 gene is mapped to chromosome 1p36 
(Fonatsch et al. 1992), like other members of this super-family, such as the human TNFR2 
and OX40 (Kemper et al. 1991), (Latza et al. 1994). It is noteworthy that a variant CD30 
transcript encoding a truncated CD30 protein that lacks the extracellular, transmembrane and 
part of the cytoplasmic domain is expressed in some myeloid and lymphoid cells (Horie et al. 
1996; Horie et al. 1999). 
 CD30L is a type II, 40 kDa membrane glycoprotein. The human CD30L gene is 
mapped to chromosome 9q33. Human CD30L protein has an extracellular domain comprising 
C- terminal 172 amino acids, and a cytoplasmic domain of N-terminal 40 residues (Fig. 2). 
The extracellular domain shows significant homology to TNF-alpha, TNF-beta  and the 
CD40L. Like other TNF family proteins, CD30L also forms a trimer, which is considered to 
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be the functional form. It was shown that only the immobilized recombinant CD30L appears 
to be functional (Smith et al. 1993; Gruss et al. 1994) and furthermore, it is presently unclear 
whether CD30L also exists as a soluble form like TNF-alpha and FasL (Smith et al. 1993). 
 
 
Figure 2: Schematic organization of human, murine and rat CD30 and human CD30L. N: N-terminus of 
the protein and C: C-terminus of the protein. 
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CD30 was originally identified as a surface marker in Hodgkin and Reed Sternberg (H-RS) 
cells of HL using anti-CD30 monoclonal antibody (MAb) Ki-1 (Schwab et al. 1982; Stein et 
al. 1985). However, over-expression of CD30 is not an exclusive feature of HL, but also of 
some non-Hodgkin lymphomas (NHL) including Burkitt’s lymphomas (Jones et al. 1995), 
mediastinal large B-cell lymphomas (Higgins and Warnke 1999) and especially anaplastic 
large cell lymphomas (ALCL) (Stein et al. 2000; Morris et al. 2001). CD30 expression can 
also be induced by various stimuli. In vitro, expression of the receptor on PBLs is caused by 
mitogens like phytohemagglutinin (PHA), IL-2 or viral infections such as HTLV-1, -2, HIV, 
and EBV (Stein et al. 1985; Schwarting et al. 1989; Falini et al. 1995). Preferentially, CD30 
expression is restricted mainly to activated lymphoid cells – B, T and NK cells (Andreesen et 
al. 1984; Cambiaggi et al. 1993). 
CD30 ligand (CD30L) was identified using a CD30-Fc fusion protein on the surface 
of anti-CD3 stimulated human PBMC and the murine T cell line 7B9 (Smith et al. 1993). 
Under physiological conditions the expression of CD30L was evident on activated T cells, 
granulocytes, monocytes/macrophages (Smith et al. 1993; Armitage 1994) and the medulla of 
the thymus (epithelial cells and Hassals corpuscles) (Romagnani et al. 1998) as well as on 
resting and malignant B lymphocytes (Younes et al. 1996). CD30L is also expressed in 
various diseases such as Burkitt lymphoma, acute myeloid lymphoma, and B cells in 
lymphoproliferative disorders (Gruss 1996; Pinto et al. 1996; Gattei et al. 1997). In tissue 
sections of ALCL, CD30L expression was not detected. In contrast, the majority of HL tissue 
sections were positive for CD30L staining, revealing a co-expression of CD30 receptor and 
ligand (Hsu and Hsu 2000). 
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The extra-cellular part of the membrane-bound CD30 can be proteolytically cleaved by the 
action of zinc-metalloproteases (Hansen et al. 1995). This produces a soluble form of CD30 
(sCD30) with a molecular mass of 85-90 kDa (Josimovic-Alasevic et al. 1989). Shedding of 
CD30 occurs as an active process of viable CD30-positive cells. Increased serum sCD30 
levels have been noted in various conditions like infections (HIV-1, EBV, HTLV-1, and 
hepatitis B virus), autoimmune disorders (RA, SLE, systemic sclerosis, atopic dermatitis, 
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Grave’s disease, Wegener’s granulomatosis, and Omen’s syndrome) and neoplasms (HL, 
ALCL, ATL, ALID like T-cell lymphoma) and correlated with disease activity, in most 
subjects (Pfreundschuh et al. 1990; Pizzolo et al. 1990; Pizzolo et al. 1990; Nadali et al. 1994; 
Pizzolo et al. 1994; Caligaris-Cappio et al. 1995; Fattovich et al. 1996). In HL, it is suggested 
that levels of sCD30 can be used as a prognostic factor. It is of particular interest that 
CD30L
+
 cells (neutrophils, mast cells and eosinophils) could play a major role in 
pathogenesis of lymphoma (Kuppers 2009). The relevance of CD30 activation in HL 
pathology is still uncertain and only a limited number of studies have addressed the 
contribution of CD30L expressing cells. The activation of HRS cells by CD30L results in a 
proliferative response in the tumor cells, and this might be one reason for the negative 
prognostic impact associated with the presence of large numbers of eosinophils and mast cells 
in HL (Gruss et al. 1996; Pinto et al. 1996; Molin et al. 2002). The above studies were 
performed with recombinant immobilized CD30 protein. However, the impact of CD30 in the 
Hodgkin environment has been still a puzzle to understand the pathogenesis of the disease.  
Because CD30 expression on normal cells is restricted to activated T, B, NK cells and 
eosinophils, it has been proposed as a target for antibody-based immunotherapy of HL. Few 
studies have demonstrated that anti-CD30 monoclonal antibodies (mAbs) can be effective in 
inhibiting the growth of HL cells in severe combined immunodeficiency mice (Wahl et al. 
2002; Borchmann et al. 2003). Interestingly, these antibodies inhibited the growth of HL cells 
in vitro in the absence of immune effector cells, suggesting direct cytotoxic potential for the 
antibodies. 
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Recent advances in studies of signal transduction pathways of the TNFR super-family 
revealed that signals of many, if not all members, are mediated through interaction with two 
groups of signal transducers, the TNF receptor-associated factors (TRAFs) and proteins with 
a death domain (FADD and TRADD). CD30 mediated signaling is transmitted by interaction 
with TRAFs, which are attached to the cytoplasmic tail of CD30 after receptor stimulation 
(Wajant et al. 1999). Upon CD30 stimulation, the adapter molecules TRAFs induce different 
signaling mechanisms promoting various biological responses such as cell survival and cell 
death. 
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CD30 lacks the death domain of TNF receptor 1 and Fas antigen, which is required for 
transduction of an apoptotic signal. CD30-CD30L associated cell death relies on interaction 
of the cytoplasmic domain of CD30 with TRAF-1, 2, 3 and 5 (Ansieau et al. 1996; Gedrich et 
al. 1996; Hsu et al. 1996; Aizawa et al. 1997; Boucher et al. 1997; Duckett et al. 1997; 
Duckett and Thompson 1997). A previous study indicates that cytotoxic effects, induced by 
CD30, are mediated by endogenous production of TNF and autocrine or paracrine activation 
of TNF receptor 1 (Lee et al. 1996). Later, this was explained that CD30 signaling led to the 
recruitment and degradation of intracellular TRAF2 limiting the ability to induce NF-B and 
increasing the sensitivity for TNFR1-induced apoptosis (Duckett and Thompson 1997). 
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Like other TNFR super-family members, CD30 has been shown to activate the NF-B 
pathway as well as MAPKs i.e extracellular-regulated kinase (ERK), Jun N-terminal kinase 
(JNK) and p38. Activation of JNK and p38 require the recruitment of TNF receptor-
associated factors (TRAFs) to the CD30 cytoplasmic domain (Duckett et al. 1997; Harlin et 
al. 2002; Zheng et al. 2003). It is described that these adapter molecules lead to activation of 
I-B kinases and NF-B kinase (NIK), which phosphorylate I-Bs and thereby activate NF-
B (Kucharczak et al. 2003). Activation of NF-B is mostly regulated by TRAF2, TRAF5 
and TRAF6 (Aizawa et al. 1997; Horie et al. 1998). This activation is reflected by the 
expression of several NF-B regulated targets, e.g, A20, cellular inhibitor of apoptosis 
protein 1-2 (cIAP), cellular FLICE inhibitor protein (c-FLIP), and TRAF1 (Durkop et al. 
2003; Mathas et al. 2004; Durkop et al. 2006).  
NF-B activation by CD30L cross-linking was also observed in the HL cell line L540 
and promotes cell survival (McDonald et al. 1995). In contrast, stimulation of the ALCL-
derived cell line Karpas299 resulted in drastic decrease of cell growth by CD30 mediated cell 
death (Smith et al. 1993) leading to the hypothesis that activation of CD30 might induce 
opposite effects in HL and ALCL cells. Furthermore, a recent report demonstrated that 
CD30-induced signaling is absent in classical HL but present in ALCL (Hirsch et al. 2008). 
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Restricted expression of CD30 on activated T cells indicates a role of CD30 in the T-cell 
dependent immune response, a characteristic function shared with some other members of 
TNFR super-family (Horie and Watanabe 1998). CD30 stimulates proliferation of peripheral 
blood T cells in the presence of TCR stimulation (Gilfillan et al. 1998). CD30 can also 
activate T cells to produce cytokines. The production of IL-2, TNF-alpha and IFN-gamma by 
human peripheral blood T cells activated by phytohemagglutinin (PHA), was enhanced by 
CD30 signals (Gruss and Herrmann 1996). It was also shown that IL-5 release by cytotoxic T 
lymphocytes (CTLs) was induced by CD30 stimulation (Bowen et al. 1996). These results 
provided evidence that CD30 can function as a co-stimulatory receptor. 
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The interaction between CD30 and its ligand constitutes a bidirectional interaction, whereby 
not only CD30
+
 cells can be activated by CD30L but also the CD30L
+
 cells can be activated 
by CD30. This mechanism is described as reverse signaling (Fig. 3). CD30L has a 
cytoplasmic tail consisting of 37 amino acids, conserved between species, a feature that 
makes signal transduction feasible. Examples of such reverse signaling have been shown for 
various TNF family members, including CD40 ligand, OX40 ligand, and Fas ligand (Stuber 
et al. 1995; van Essen et al. 1995; Suzuki and Fink 1998). Signaling downstream of CD30L is 
reported to induce proliferation of T cells and IL-6 production by T cells, IL-8 production and 
a strong, rapid oxidative burst in neutrophils (Wiley et al. 1996),  impaired immunoglobulin 
isotype switching in B cells (Cerutti et al. 2000) and IL-8 release by mast cells (Fischer et al. 
2006). The mechanism of CD30L mediated reverse signaling with other cell types of the 
immune system such as DCs and granulocytes is still unclear. Thus, this project focuses on 
the possible role of CD30L-CD30 signaling in dendritic cells and granulocytes. 
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Figure 3: Bidirectional Signaling of CD30-CD30L 
Engagement of CD30 receptor on H-RS cells by CD30L on other immune cells leads to NF-B activation or 
apoptosis. Ligand-expressing cells were also activated, leading to generation of reactive oxygen species (ROS) 
and pro-inflammatory cytokines. 
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Mature dendritic cells are antigen-presenting cells (APCs) that activate T cells and induce 
antigen-specific T-cell responses.  
Upon inflammation, the progenitor cells or DC precursors (monocytes) are 
transformed into immature dendritic cells (iDC). These cells are characterized by high 
endocytic activity and low T-cell activation potential. Immature DCs present antigens to T 
cells, which in the absence of appropriate co-stimulation lead to tolerance. This mechanism is 
one of many that permit to control auto-reactive T cells. In contrast, DCs undergo maturation, 
when stimulated by microbes, toll-like receptor (TLR) ligands, activated T and NKT cells 
(through CD40L), or NK cells (through NKp30) and pro-inflammatory cytokines. Then, DCs 
are geared towards the launching of antigen-specific immunity finally leading to T-cell 
proliferation and differentiation into helper and effector profiles (Cella et al. 1996; McLellan 
et al. 1996; Bereta et al. 2004; Schmitz et al. 2006; Steinman 2007; Steinman and Banchereau 
2007). Therefore, the complex mechanism of DC maturation is a key event for the generation 
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of an immune response. A better understanding will expand our basic knowledge and is also 
important for the development of novel immunotherapeutic strategies. 
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The major cells of the lymphoid lineage that interact with DCs to shape the immune response 
are NK cell. NK cells lack antigen-specific receptors but are capable of killing virus infected 
cells or tumor transformed cells without antigen-specific prior activation. These are generally 
regarded as part of the innate immune system, but also play a role in DC maturation leading 
to an enhanced/controlled adaptive immune response (Gerosa et al. 2002; Piccioli et al. 2002; 
Gerosa et al. 2005). Recently, there has been emerging evidence for the importance of the 
interaction between human NK cells and DCs. The NK-DC interaction is a reciprocal 
activation that functions as an important control switch for amplifying or attenuating innate 
immune responses (Ferlazzo et al. 2002; Gerosa et al. 2002; Zitvogel 2002). Thus, these two 
cell types can potentially activate each other in their maturation process; DCs activate NK 
cells during the process of priming the innate response and in turn the NK cells promote the 
DC maturation by cytokine production. This bidirectional signaling between NK-DC might 
take place at different stages of the innate and adaptive immune responses indicating that this 
cross-talk links the innate and adaptive immunity (Moretta 2002). 
The bidirectional cross-talk begins with the recruitment of these cells to the site of 
inflammation. Upon inflammation or infection there is a release of type-I IFNs and 
chemokines (Biron et al. 1999). This stimulus recruits the NK cells from the blood stream. 
Both the resident and simultaneously recruited DCs are then able to promote NK-cell 
activation. The cytotoxic effect of these activated NK cells on the surrounding iDCs is 
dependent on natural cytotoxicity receptor, NKp30 and its exosomal ligand BAT3 (Ferlazzo 
et al. 2002; Simhadri et al. 2008).  
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Figure 4: NK-DC cross-talk 
Interaction of NK and DC connects both innate and adaptive immune responses (Walzer et al. 2005). (Top) 
Inflammation, tumor transformation and virus infection lead to maturated DCs (mDC) mediated by toll-like 
receptors with IFN-. This process stimulates cytokine release and lead to the activation of NK cells (aNK). 
(Middle) The activated NK cells release a set of cytokines (TNF-alpha and IFN-gamma) that promote iDC 
maturation. (Bottom) Activated NK cells were induced through TRIAL (TNF-related apoptosis-inducing ligand) 
pathway to eliminate excess iDCs, thus providing the quality of adaptive immune response. 
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NK-cell activation by tumor cells has been shown to promote the elicitation of cognate and 
protective T-cell responses against the tumor. In some cases, T cell-mediated tumor rejection 
was shown dependent on DC activation by NK cells (Mocikat et al. 2003). IFN-gamma 
secreted during NK cell-mediated tumor rejection is critical for cytotoxic T lymphocytes 
(CTL) generation, particularly when tumors express CD70 or CD80 and CD86 (Kelly et al. 
2002). Furthermore, Adam et al. reported that NK-cell-DC crosstalk may by-pass the T 
helper arm in CTL induction against tumors expressing NKG2D ligands (Adam et al. 2005). 
Mutual activation of NK cells with other immune regulatory cells is mediated by several 
receptor-ligand interactions particularly NKp30 with its ligand BAT3, NKG2D with its 
ligands ULBP1-3 and MICA/B, DNAM-1 with PVR and Nectin-2 and NKp80 with AICL 
(Newman and Riley 2007; Pogge von Strandmann et al. 2007; Simhadri et al. 2008). 
The Vujanovic group has shown that DC and NK cells constitutively express several 
TNF family ligands and corresponding TNF family receptors, these receptor-ligand pairs 
greatly impaired DC-NK cell abilities to reciprocally mediate the increases in cytokines 
(Makarenkova et al. 2005). Recent reports described that the cognate interaction of TNF-
TNFR2 is essential for mouse DC-NK cell cross-talk (Xu et al. 2007). These finding indicate 
TNF and some other members of TNF family ligands might be important mediators of DC-
NK interaction and reciprocal stimulation. Therefore, this study extends the above 
observations on the function of NK-DC cross-talk with the involvement of CD30-CD30L 
interaction. 
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Ligands of the tumor necrosis factor super-family (TNF-SF) and the corresponding receptors 
have been the subject of extensive investigation during the last decades. Although CD30, a 
member of TNF receptor super-family and CD30L, member of TNF ligand super-family were 
identified and cloned long ago, it is still challenging to define the consequences of CD30-
CD30L interactions at both molecular and cellular levels. 
CD30 is differentially expressed on almost all activated immune effector cells and over-
expressed in some malignant lymphomas. Previous studies describe that engagement of CD30 
on CD30
+
 lymphoma results in H-RS cell survival in HL, cell-growth arrest in ALCL or Th1-
mediated responses in RA. In these diseases, the ectodomain of CD30 is shed in the 
inflammatory region. The effect of sCD30 on CD30L
+
 cells is not clearly elucidated. 
Moreover, the exact function of surface-expressed CD30 on normal activated NK cells was 
not yet addressed. On the other hand, CD30L shows greater homology to other TNF ligand 
members and is expressed on stimulated hematopoietic cells during the inflammatory 
response. It is well described that interaction between CD30 and CD30L effects not only the 
receptor bearing cells but also induce specific downstream signaling to ligand-bearing cells. 
With respect to CD30L, definition of its biological role remained elusive because its 
expression on different immune cells (granulocytes and DCs) is controversially discussed. 
In recent years, there has been emerging evidence that NK cells interact with other immune 
cells such as DCs, mast cells, eosinophils, basophils and neutrophils during inflammation. 
Among these interactions, cross-talk between NK cells and monocyte-derived DCs has been 
the major focus. Recent studies indicate that NK cell activation induced by DCs requires the 
synergistic action of several cytokines and direct contact between DCs and NK cells. The 
requirement for cell-cell contact is likely to reflect (i) the implication of membrane bound 
receptor-ligand pairs; and/or (ii) the necessity for local delivery of cytokines at high 
concentration at the interface between DCs and NK cells. 
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The goal of the study is to elucidate the role of CD30-CD30 ligand-dependent signaling for 
the communication among immune effector cells that is mediated either through cell-cell 
contact or through the soluble CD30. For this the following issues will be addressed: 
(i) Establishment of the expression pattern and functional properties of CD30L on 
dendritic cells 
(ii) Functional investigation of the CD30-CD30L interaction in NK-DC cross-talk 
(iii) Elucidation of the expression profile of CD30L on granulocytes 
(iv) Characterization of the CD30L-mediated cellular response of granulocytes to 
soluble CD30  
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293T Human Fibroblast kidney cell line (ATCC, Manassas, USA)  
L540 Human Hodgkin’s Lymphoma cell line (a gift from Prof. V. Diehl, Koeln) 
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Table 1: 
Vector Fusion Selection marker 
(Bacteria) 
Selection marker 
(Mammalian cells) 
pcDNA 3.1 No tag          Ampicillin           Zeocin 
pFuse 2
 
Fc-fragment of 
human IgG1
 
          Zeocin           Zeocin 
pIG (pCDM8)
 
Fc-fragment of 
human IgG1
 
         Ampicillin      No resistance 
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Different bacterial strains Escherichia coli (E.coli) used for molecular biology: 
DH5, XL-1 blue, TG-1, BL-21 (DE3) and MC-1061. 
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Table 2: 

Antigen 
Fluoro-
chrome Company 
Against 
species 
From 
species 
Iso-
type clone 
CD3 Purified BD Biosciences human mouse IgG2a HIT3a 
CD3 FITC BD Biosciences human mouse     
CD3 PE Immuno Tools human mouse IgG1 UCHT1 
CD3 APC Immuno Tools human mouse IgG2a MEM57 
CD3 percp BD Biosciences human mouse   
CD4 APC BD Biosciences human mouse   
CD9 purified BD Biosciences human       
CD14 FITC BD Biosciences human       
CD14 PE BD Biosciences human mouse     
CD16 purified BD Biosciences human       
CD16 PE BD Biosciences human mouse     
CD30 purified 
Laboratory of 
Immune therapy 
human human   5F11 
CD30 (Ki-1)  Purified 
Dr. Lemke, Kiel 
human mouse IgG3  
CD30 (Ki-2) Purified 
Dr. Lemke, Kiel 
human mouse IgG1  
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CD30 (Ki-3) Purified 
Dr. Lemke, Kiel 
human mouse IgG2b  
CD30-BerH2 Purified 
Dr. H. Stein, 
Berlin 
human mouse IgG1  
CD30-HeFi-1 Purified 
Dr. T. Ellis, 
Chicago  
Human Mouse IgG1  
CD30 PE BD Biosciences human mouse     
CD30L purified R&D Systems human  mouse IgG2b 210845 
CD56 FITC Immuno Tools human  mouse   
CD56 PE BD Biosciences human mouse    
CD56 APC BD Biosciences human mouse     
CD1a PE BD Biosciences human mouse     
CD1a APC Bio legends human mouse     
CD83 FITC BD Biosciences human mouse     
CD80 FITC BD Biosciences human mouse     
CD80 PE Bio Legends human mouse     
CD86 purified Immuno Tools human mouse     
CD86 FITC BD Biosciences human mouse     
CD86 PE BD Biosciences human mouse     
NKp30 PE 
Beckman Coulter 
human mouse IgG1 Z25 
NKp44 PE 
Beckman Coulter 
human mouse IgG1   
NKp46 purified BD Pharmingen human mouse   9E/2 
NKp46 PE 
Beckman Coulter 
human mouse IgG1 BAB281 
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Kp46 APC BD Biosciences human mouse IgG2b   
hNKG2D PE BD Biosciences human mouse IgG1   
NKG2D Fitc Abcam human mouse IgG1 1D11 
hNKG2A PE BD Biosciences human mouse IgG2a    
HLA-ABC purified BD Biosciences human mouse IgG1 G46-2.6 
HLA-DR purified BD Biosciences human mouse     
HLA-A,B,C PE BD Biosciences human mouse     
HLA-DR FITC BD Biosciences human mouse     
IgG Fc purified Dianova human goat F(ab)2 
  
IgG purified Dianova   goat IgG   
IgG H+L purified Dianova mouse goat F(ab)2   
IgG PE BD Biosciences human mouse     
human IgG1 
PE BD Biosciences mouse goat     
IgG APC BD Biosciences human mouse     
7-AAD 7-AAD BD Biosciences         
Annexin V PE BD Biosciences         
anti-mouse FITC BD Biosciences mouse goat poly   
anti-mouse PE Dako mouse goat poly   
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The following reagents were used: Human recombinant GM-CSF, IL-4 and TNF-alpha  
(Immunotools, Germany), 8-chamber microscopy slides (Nalgen, Nunc International Corp, 
Naperville, USA), 2
’
,7
’
-Dichlorofluorescein diacetate (DCFH-DA), Phorbol myristate acetate 
(PMA), Lipopolysaccharide (LPS), and Carboxy-fluorescein diacetate succinimidyl ester 
(CFSE)  (Sigma Aldrich Inc, St. Louis, USA), MAP kinase inhibitors PD98059, SB203580, 
and SP600125 (Calbiochem-Novabiochem, San Diego, USA), Protein A sepharose beads 
(GE Healthcare, Freiburg). NK cell, Pan T cell and Blood DC isolation Kits were purchased 
from Miltenyi, Bergisch Gladbach, Germany).  
All the laboratory chemicals and other reagents were purchased from Roth Chemicals and 
Sigma Life Sciences. 
All the oligo-nucleotides used for amplifying the desired gene products were obtained from 
MWG-Biotech, Ebersberg, Germany. 
Synthetic Oligonulceotides 
Table 3: 
Primer Name                 Oligonulceotide Sequence  (5'-------------- 3') Restriction 
Endonuclease 
CD30 D1-2 for gcgagaagcttatgcgcgtcctcctcgccgcg HindIII 
CD30 D1-2 rev ccggaattcgcaggtgcgggaggagttc EcoRI 
CD30 stalk for ccggaattcaaccccaccccagagaatggcgag EcoR1 
CD30 stalk rev gacggatccacttacctgtttcgcaggtgcgggaggagttcca BamH1 
CD30 D1 for gcgagaagcttatgcgcgtcctcctcgccgcg HindIII 
CD30 D1 rev gatggaattcgcagtcagtaggcctctgagggcac EcoR1 
CD30 D6 for acccctcgagtgtcgacctggcatgatctgtgccac Xho1 
CD30 D6 rev gacggatccacttacctgtttcgcaggtgcgggaggagttcca BamH1 
Leader seq for gcgagaagcttatgcgcgtcctcctcgccgcg HindIII 
Leader seq rev gacactcgaggggtcgatcctgtgggaaggctcgt Xho1 
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Construction of desired cDNA into expression vectors 
 
The construction of pcDNA3.1-CD30 (wt) (CD30 full length), a kind gift from Dr. Hinrich 
Hansen was described previously (Hansen et al. 2004). The ectodomain of CD30 is 
comprised of six domains where in the last three domains are exactly the pictures of the first 
three domains. The constructs pIgG1-LCD30-Ig (all domains), pIgG1-MCD30-Ig 
(Domain-1, 2/5 and 6) and pIgG1-SCD30-Ig (Domain-1 and 6) were a kind gift from Dr. 
Hinrich Hansen (Hansen et al. 2004; Eichenauer et al. 2007). The other deleted CD30 
variants were constructed using the oligonucleotides mentioned in the Table 2.   
 
pIgG1-D1-2 CD30-Ig (Domain-1 and 2/5) 
The construct was generated using multiple cloning steps. 
A) D1-2 CD30 (domain1 and 2/5) was amplified using pIgG1-CD30M as a template with 
primers CD30 D1-2 for and CD30 D1-2 rev. Subsequently, the amplified product was 
digested with HindIII and EcoRI restriction enzymes and sub-cloned into pEGFP-C1 (used as 
a cloning vector to maintain the frame with pIg vector) named as pEGFP-C1 CD30 D1-2/5. 
B) The stalk domain of CD30 was amplified using pIgG1-CD30M as template with primers 
CD30 stalk for and CD30 stalk rev. The amplified stalk domain was inserted into the above 
construct pEGFP-C1 CD30 D1-2/5 using EcoR1 and BamH1 restriction sites. 
C) As a final step, CD30 D1-2/5 with stalk domain was digested from pEGFP-C1 using 
HindIII and BamH1 and sub-cloned into pIgG1 CD30, replacing the full-length ectodomain 
of CD30 to be in frame with human-IgG. 
 
pIgG1- D1CD30-Ig (Domain-1) 
A CD30 variant only with Domain-1 was amplified using pIgG1-CD30M as template with 
primers CD30 D1 for and CD30 D1 rev. The amplified products were subsequently digested 
with HindIII and EcoR1 and inserted into the expression vector (pIgG1) in frame with 
human-IgG. 
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pIgG1- D6CD30-Ig (Domain-6)  
The construct was generated in two steps. 
(A) Domain-6 of the ectodomain was amplified using pIgG1-MCD30 as template with 
primers CD30 D6 for and CD30 D6 rev. The amplified PCR product was digested with Xho1 
and BamH1 and inserted into the expression vector (pIgG1) in frame with the Fc-fragment of 
human-IgG1. 
(B) Next, the leader sequence was generated using pIgG1-MCD30 as a template with primers 
leader seq for and leader seq rev. The PCR product was sub-cloned into above construct to 
enable the synthesized protein to be released into the cell culture supernatants. 
 
pGEX-3T CD153 (CD30 ligand) 
The cDNA for CD153 flanked by BamHI and EcoR1sites was amplified and ligated into the 
pGEX-3T vector (GST- as a tag expressing in bacteria). 
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Isolation of plasmid DNA from E.coli 
Isolation of plasmid was performed using Qiagen kit according to the manufacturer’s 
protocol. In brief, bacteria (E.coli strains DH5, MC-1061, XL1-Blue) were cultivated for at 
least 12-16 hours in LB-Medium with respective antibiotics (e.g.100 g/ml Ampicillin) at 
37°C. The cells were harvested, and were subjected to alkaline lysis and the plasmid-DNA 
was isolated. The purified plasmid was quantified and confirmed using restriction enzyme 
analysis. 
Quantification of DNA and RNA 
DNA and RNA samples were diluted in ddH2O before they were measured in Bio-Rad Smart 
Spec 3000 Spectrophotometer. The measured wavelength is 260 nm; concentrations are 
calculated by the conversion factors 50 μg/ml for double stranded DNA and 40 μg/ml for 
RNA. The purity of the DNA preparation is given by the ratio of Abs 260 nm/280 nm. While 
Materials and Methods 
 
1.8 is ideal, lower values point to contaminations with proteins and aromatic substances 
whereas higher ratios indicate possible contaminations with RNA. 
Polymerase Chain Reaction (PCR) 
PCR can be used for in vitro amplification of DNA fragments. A double stranded DNA 
(dsDNA) serving as a template, two oligonucleotides (primers) complementary to the 
template DNA, deoxyribonucleotides (dNTPs) and heat resistant Taq-DNA-polymerase (from 
Thermus aquaticus) are required for this reaction. When a proofreading activity was 
necessary, Pfu-DNA-polymerase (Pyranococcus furiosus) was used. 
Primers may be designed having non-complementary ends with sites for restriction enzymes. 
First step in PCR reactions is the denaturing of dsDNA at 94°C. Second, the reaction mix was 
incubated at different annealing temperatures, depending on the G/C content of the primers. 
Different programs provide an accurate calculation of the annealing temperature and other 
primer properties. The specific annealing temperature for the primers was obtained using the 
formula: TA = TM – 5
o
C where, {TM = 4 (G + C) + 2 (A + T)}. The third step with a 
temperature of 72°C allows elongation of the new strand of DNA by the polymerase. The 
time for this step depends on the fidelity of the polymerase. In general a high fidelity 
polymerase, such as Taq, requires shorter elongation time, whereas Pfu requires longer 
elongation times. 
Agarose Gel Electrophoresis. 
Agarose gel electrophoresis was performed to analyze the length of DNA fragments after 
restriction enzyme digests and PCR, as well as for the purification of PCR products and DNA 
fragments. DNA fragments of different molecular weight show different electrophoretic 
mobility in an agarose gel matrix. Optimal separation results were obtained using 0.8-1 % 
(w/v) agarose gels in TAE buffer at 15 V/cm. Horizontal gel electrophoresis apparatus of 
different sizes were used. Before loading the gel, the DNA sample was mixed with 1/6 
volume of the 6x DNA-loading buffer. For examination of the DNA fragments under UV-
light, agarose gels were stained with 0.1 g/ml Ethidium bromide. In order to define the size 
of the DNA fragments, DNA molecular standard markers were also loaded on the gel. 
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Gel Extraction of DNA 
Elution of DNA fragments from agarose gels was performed after excising the band of 
interest from the agarose gel and using the Qiagen gel extraction kit according to the 
application manual. Eluted DNA was dissolved in appropriate volume of 10 mM Tris-HCL, 
pH 8.5 or water. 
Ligation of DNA 
T4-DNA-ligase (Fermentas) catalyzed the ligation of isolated DNA fragments and linearized 
vector DNA. The desired DNA fragment (s) were ligated with respective vector (s) at ratio 
(insert: vector = 3: 1) in 20 μl ligation reaction (0.5 U T4-DNA-Ligase; 1 l T4-Ligation 
buffer) for 5-10 minutes at room temperature. 
Preparation and transformation of competent bacteria  
Preparation of Competent Bacteria 
Single bacterial colony of the specific strain of E.coli was picked from LB-agar plate and 
grown over night in LB media at 37
o
C. Next day the bacterial culture was diluted 1:100 and 
grown till an optical density (OD) at 0.6-0.8. Bacterial culture was cooled down for 10 
minutes in an ice-cold water bath before pelleting the bacteria 10 min, 800 X g at 4
o
C. The 
pellet was re-suspended in 15 ml TFB1 buffer (buffer section) and incubated 10 minutes at 
4
o
C. After centrifuging the bacteria (10 min, 800 X g, 4
o
C, they were re-suspended in 2 ml 
TFB II buffer. 200 ml aliquots of the chemo-competent bacteria were shock-frosted in liquid 
nitrogen and stored at -80
o
C. 
Transformation of competent E.coli cells 
100 μl competent E.coli were incubated with the ligation reaction (usually 7 μl) for 30 
minutes on ice. Afterwards the transformation mix was heat shocked at 42
o
C for 50 sec and 
immediately placed on ice for 2 minutes. The mix was re-suspended in 900 ml LB media 
without antibiotic, and incubated at 37
o
C with shaking for at least 45 minutes. Cells were 
collected by centrifugation in table-top centrifuge 2000 X g for 5 minutes and plated on LB-
agar plates supplemented with appropriate antibiotics (e.g.100 μg/ml ampicillin). The plates 
were incubated at 37
o
C for overnight.  
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Estimation of Protein Concentration 
Protein concentration was estimated by colorimetric analysis using the Bi-Cinchoninic Acid 
(BCA) Protein Assay (Thermo Scientific, Pierce). Protein standards dilutions of BSA were 
used to construct a standard curve (five concentrations: 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 
mg/ml, and 0.125 mg/ml). Several dilutions of the protein sample were mixed and measured 
at 562 nm. The concentration was automatically correlated to the data for the standards and 
the protein concentration was recorded as mg/ml. 
SDS-Poly-Acrylamide Gel-Electrophoresis (SDS-PAGE) 
In presence of Sodium Dodecyl Sulfate (SDS), proteins with different molecular weight show 
different electrophoretic mobility in a denaturative polyacrilamide gel. Protein samples mixed 
with SDS-sample buffer were heated, when necessary, for 5 minutes at 95°C prior to loading 
on the gel. Biorad Mini-Protean gel running system was used for running the gels. At the 
completion of the run, gels were either stained with Coomassie-blue or transferred onto a 
PVDF or nitrocellulose membrane for Western blot analysis. 
Western Blotting (Transfer of Proteins) 
Western Blotting is a technique that allows the transfer of proteins from a poly-acrylamide 
gel onto the membrane. In this work the wet blotting method was used: Two layers of 
Whatmann paper, soaked in Blotting buffer, were placed on the blotting chamber.  Then the 
membrane and the gel all soaked in Transfer buffer were overlaid. Finally, two layers of 
Whatmann paper, in Blotting buffer, where placed on top. The transfer was performed at 250 
mA for 90 minutes. Membranes were stained with Ponceau S (Bio-Rad) for assessment of 
blotting efficiency and marker detection prior to immuno-detection. 
Protein detection on membrane 
After protein transfer on membrane, the latter was incubated in blocking solution (5% w/v 
milk powder in TBS-Tween buffer or using Roti-Block) for 60 minutes. Antibodies (serum 
diluted in blocking solution) were incubated for 60 minutes at RT or for over-night at 4
o
C, 
followed by 3 times washing with TBS-Tween buffer. Peroxidase conjugated secondary 
antibodies were applied for 60 minutes at RT. Membranes were washed 3 times for 10 
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minutes with TBS-T buffer and treated with Luminol 1 and Luminol 2 solutions. Thus 
treated, the membranes were exposed to X-ray film for 5 seconds to 1 hour depending on the 
strength of the signal. 
Stripping of nitrocellulose membranes 
When membranes had to be stained with another antibody, they were treated for 15-30 
minutes with 100 mM Glycin-HCL, pH 2.5 and washed for 10 minutes with TBS-T buffer. 
Purification of monoclonal antibody from hybridoma culture Supernatant  
Step1: Hyridoma cell culture  
• A frozen aliquot of mouse monoclonal (HeFi-1) that express monoclonal antibody 
(subtype IgG1) against CD30 epitope was thawed and cutltured in RPMI-1640 
medium containing 10% FBS and incubated at 37
o
C with 5% CO2. 
• Once the cells were grown to 90% confluent stage, the medium was replaced by 
serum-free hybridoma medium. 
• The supernatant was collected for every two days (3 times) and stored at -20
o
C. 
Step2: Affinity purification of antibody  
• Appropriate volume of protein-A sepharose column was set according to the general 
principle: culture supernatant contain 20-50 μg/ml of antibody, 1 ml of wet beads 
(slurry) bind approximately 10-20 mg of antibody. The column was washed with 
50mM Tris buffer pH 8.0. 
• The filtered culture supernatant was adjusted to pH 8.0 by adding 1/10 volume of 1.0 
M Tris buffer pH 8.0, and allowed to pass through the column at the flow-rate of 1ml 
per minute. 
• The column was washed thoroughly with at least 10 column volumes of 50 mM Tris 
buffer.  
• The antibody was eluted with 100 mM glycine (pH 2.7), and immediately the pH was 
adjusted to pH 8.0 with Tris buffer. 
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• The eluted antibody was dialyzed against PBS (pH 7.4) and the concentration was 
determined by BCA-protein assay. 
Horse Radish Peroxidase (HRP) labeling of antibody 
The procedure has three major steps  
• Activation of HRP: To activate HRP, 4 mg of HRP was dissolved in 1 ml of distilled 
water and 0.2 ml of freshly prepared 0.1 M Sodium Per-iodate (NaIO4) was added and 
incubated for 20 minutes at 25
o
C, followed by a dialysis step with 1mM Sodium 
Acetate (pH 4.4) at 4
o
C. 
• Preparation of antibody solution: 1 ml of antibody solution (2 mg/ml) was dialyzed 
overnight at 4
o
C in buffer containing 10 mM Potassium Phosphate (pH 8.0) and 50 
mM Sodium chloride for overnight at 4
o
C. 
• Labeling of antibody: The dialyzed HRP and antibody solutions were mixed. The 
reaction was started by addition of 40 μl of 0.5 M Sodium Carbonate buffer (pH 9.5). 
The antibody was incubated for 2 hr at 25
o
C, and further incubated 2 hr at 4
o
C with 
0.1 ml of Sodium borohydride (4 mg/ml in H2O). Finally, the antibody was dialyzed 
against PBS. The antibody was stabilized with BSA (0.1 mg/ml) and few grains of 
thymol and stored at -80
o
C. 
Purification of CD30 Ig and human Ig 
The truncated CD30-Ig was gifted by Dr. Hinrich Hansen (Eichenauer et al. 2007). CD30-Ig 
and human-Ig (pFuse-hFc2 purchased from Invitogen) were transfected to 293T cells a 
human fibroblast kidney cell line. After 48 hr of transfection supernatants were collected and 
purified using Protein A sepharose (GE Healthcare). The purity was analyzed by SDS-PAGE 
and the concentration was determined by BCA-protein assay. 
Soluble CD30 (sCD30) purification 
Approximately 4x10
6
/ml L540 cells were washed once with serum free cold media, incubated 
for 90 minutes at 37
o
C in serum free media. Supernatant was collected and removed the cells 
and filtered with 0.2 m, followed by ultracentrifugation for 60 minutes at 40,000 RPM. Run 
the supernatant in NHS activated (anti CD30) Ki-2 column or isotype matched column. Wash 
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the column with 75 mM Tris with pH 8 and eluted with 100 mM Glycine at pH 2.7. The 
sample was dialyzed against PBS at 4
o
C. 
RT-PCR Analysis of CD30L 
To evaluate the expression of CD30L mRNA, RNA was isolated from iDCs (1x10
6
) and used 
1 ng of RNA was converted to cDNA by reverse transcriptase at 37
o
 C for 1 hr. PCR reaction 
was performed using the following primers;  
Forward primer:  5 GAGGAATTCGGTTCAGAGGACGGACTCCATTCCCAAC 3 
Reverse primer:  5 GTGAAGATCTTCAGTCTGAATTACTGTATAAGAAGATGGAC 3 
Binding of CD30 to iDC 
Nearly 5 μg/ml of recombinant CD30-Ig and its variants were incubated with 1x105 cells each 
FACS tube, incubated on ice for 40 min and washed the cells twice with FACS buffer and 
followed by detected with FITC conjugated to anti-human Ig (gamma specific) antibody and 
analyzed by flow cytometry. 
Interaction of CD153 with CD30 (Pull-Down Assay) 
For pull down assays GST fusion proteins (GST alone and GST-CD153) were expressed in E. 
coli BL21-D3 cells and were immobilized on glutathione-sepharose 4B beads (Amersham). 
The purified CD30-Ig constructs were expressed in mammalian cells (293T) and purified 
from the supernatants using Protein-A column. In a typical pull down reaction ~20 μg of 
recombinant protein-coated beads were incubated with 10 g/ml of purified CD30 protein for 
30 minutes with end-over-end rotation at 4ºC. Beads were washed with buffer (TBS buffer + 
0.1% BSA + 0.1% Triton X-100) and boiled in 5X SDS sample buffer and resolved on 10% 
SDS-PAGE. The gel was processed for Western transfer and the membranes were probed 
with anti-CD30 antibodies and developed using ECL (Amersham). 
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Freezing and thawing cells 
Cells were harvested and pelleted before re-suspending them in 1 ml freezing solution 
containing 90% FCS and 10% DMSO. Immediately, the suspension was put on ice and then 
stored at -20
o
C for 1 day subsequently at -80
o
C for one week, finally stored in liquid nitrogen. 
For thawing cells, the freezing vial was taken out from the liquid nitrogen tank and 
transported on ice. Carefully, the suspension was thawed in a water bath at 37
o
C. The cells 
were transferred into a 15 ml plastic tube containing pre-warmed medium before pelleting the 
cells at 300 X g for 5 min at room temperature in order to remove toxic DMSO. After re-
suspension in fresh medium, the cells were plated in culture flasks. 
 
Generation of Dendritic cells 
The sources of cells were buffy coats acquired from healthy donors. PBMCs were separated 
by Ficoll-Plaque gradient centrifugation with Leucosep columns from Greiner bio-one 
(Solingen, Germany) and were incubated with RPMI media without FBS for 60 minutes in 
plastic culture flasks (Nunc) at 37
o
C.  Suspension cells were washed out and the adherent 
monocytes were cultured in IMDM media containing 10% FBS, IL-4 (20 ng/ml) and GM-
CSF (50 ng/ml) for differentiation. The medium was changed after 3 days and the purity of 
immature dendritic cells was assessed after 5 days culture by flow cytometry (FACS analysis) 
using fluorescence conjugated antibodies CD14, CD1a, CD80, CD86 and CD83. 
 
Purification of Blood Dendritic Cells  
Blood dendritic cells were isolated from PBMCs by using blood dendritic cell isolation kit 
11. Isolation of dendritic cells is performed in a two-step procedure. First, PBMCs are labeled 
with the Non-DC depletion cocktail, later the flow-through fraction with pre-enriched 
dendritic cells were incubated with DC enrichment cocktail, upon magnetic separation, the 
magnetically labeled dendritic cells are retained on the column and are eluted after removal of 
Materials and Methods 
 
column from the magnetic field. The cell purity was assessed by using following antibodies 
monocytes (CD14
-
), B cells (CD19
-
), NK cells (CD56
-
), and Dendritic cells (CD1a
+
). 
Maturation of dendritic cells 
In this report for in-vitro maturation, monocytes-derived immature dendritic cells were 
stimulated with different CD30-Ig fusion constructs that were immobilized as a mimic for 
membrane anchored CD30. When mentioned soluble factors (e.g. soluble CD30) were added 
into the media directly. TNF-alpha and LPS were used as positive controls. The incubation 
period for maturation was 48 hours. Subsequently, the maturation markers were assessed by 
flow cytometry. The mature dendritic cells were determined by the up-regulation of co-
stimulatory molecules like CD83, CD80 and CD86. For NK-DC co-culture, cells were 
cultured at a ratio of 1:5 (NK: DC) for 48 hours and analyzed by flow cytometry. 
Purification and Activation of NK Cells 
PBMCs were isolated as described above, and non-NK cells were depleted using the NK cell 
Isolation Kit and vario MACS. Separated polyclonal NK cells were cultivated for 2-3 days in 
the presence of RPMI supplemented with antibiotics, 10% FBS, 5 μg/ml PHA and 
recombinant IL-2 100 U/ml. The purity was analyzed with NK cell markers like NKp46, 
NKp30, CD56, CD3, NKG2D and CD30. For the preparation of NK cell clones, PHA-
activated NK cells were plated in 96-well plate as 3 cells per well and cultured with 100 U/ml 
IL-2 and irradiated PBMCs (allogenic) for 5 days and monitored for the expression of NK 
cell markers. The medium was replaced for every 2 days and the selected clones were 
cultured and analyzed further. 
Purification of T cells 
MACS 
 PBMCs were obtained from buffycoats as described above, and Pan T cells were purified by 
negative selection according to the manufacturs protocol (MACS Pan T cell isolation Kit). To 
verify the purity of the Pan T cell preparations, cells were stained with antibodies to CD3, 
CD4, CD8, CD14, CD56 and CD19 (BD pharmingen). To generate the activated T cells were 
cultured in RPMI1640 supplemented with 10% FBS, 20 mM glutamine, 100 units/ml 
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pencillin and streptomycin and 1 μg/ml phytohemagglutinin (PHA) for 2-4 days. For resting 
T cells were purified just before doing the experiment. 
 
Rosettesep Procedure 
For some experiments we have used Rosettesep Kit to prepare human T cells from stemcell 
technologies. Briefly, fresh blood was collected from normal healthy donors in EDTA 
containing tubes. Human T cell enrichment cocktail was added at 50 μl/ml of blood and 
incubated 20 minutes at room temperature, then diluted the blood sample with equal volumes 
of PBS+2% FBS. Diluted sample was overlayed on Ficoll-Paque and centrifuge for 20 min at 
1200 X g, collected the enriched T cells in-between Ficoll-Paque and plasma. Finally wash 
the T cells with PBS+2% FBS. Purity of T cells was measured by flow cytometry after 
staining with antibodies to CD3, CD4, CD8, CD14, CD56 and CD19 (BD Biosciences). 
 
Isolation of Granulocytes 
Whole blood obtained from healthy donors was collected in EDTA- containing tubes and 
diluted with equal volumes of RPMI without FCS. The diluted blood was carefully placed on 
Ficoll slowly through the walls of the falcon tube and centrifuged for 35 minutes at 350 X g 
at room temperature (RT) without brake. Supernatant was discarded and the erythrocyte 
pellet was re-suspended in the double volume of 1% polyvinyl alcohol (PVA) and allowed to 
stand for 20 minutes at RT without any agitation. During the incubation period, the 
erythrocytes settle at the bottom. The granulocytes were collected from the supernatant and 
diluted with double the volume of ice cold PBS and spun for 10 minutes at 250 X g at 4
o
C. 
The supernatant was discarded and the pellet was re-suspended and left in ice-cold water for 
12 seconds and finally washed with ice-cold PBS. The cells were re-suspended with PBS. 
 
Pappenheim staining of Granulocytes  
Cytospins were performed to fix the granulocytes onto glass slides. The fixed cells were 
stained for 3 minutes in May-Grunewald stain. The slides were washed using the buffer 
containing of 2.6 mM KH2PO4 and 2.6 mM Na2HPO4. And the slides were further incubated 
for 20 minutes with Giemsa stain diluted with 9 volumes of distilled water. Then, slides were 
washed and dried enough before proceeding to light microscopy. 
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Flow cytometry 
Cells were washed with FACS buffer (PBS+0.2% BSA+0.2%NaN3) and incubated with 
primary Ab for 40 min on ice, washed twice and followed by 20-30 minutes with secondary 
Ab incubation either by FITC or PE conjugated on ice in the dark place. After the incubation, 
cells were washed two more times and measured in FACS Calibur. Some experiments 
directly conjugated Abs was used. 
 
Immunoflorescence of dendritic cells 
Monocyte-derived immature dendritic cells were placed on poly-L-lysine coated 8 well 
chamber slides for overnight in the presence of IMDM media. The cells were washed with 
PBS and fixed with methanol for 10 minutes at -20
o
C. After the cells were washed with PBS, 
blocked with 10% FBS in PBS for 1hr at room temperature and further incubated with 
primary antibody (monoclonal CD30L Ab from R&D systems) for overnight at 4
o
C. Later 
cells were washed and stained with Alexa 594 diluted in blocking buffer. The nucleus was 
detected with Hoechst 33342 (Invitrogen). Finally washed with water and then mounted the 
slide with mounting medium (aqua poly/mount – Polysciences, Inc). The slides were 
examined in Nikon ECLIPSE E800 florescence microscope with an objective lens of 20X. 
The images were obtained at 590 nm excitation and 617 nm emissions. The images were 
processed using Adobe photoshop. 
 
Reactive oxygen Species Signaling (oxidative burst) 
Approximately 0.5x10
6
 DC/ml were stimulated with immobilized constructs at a final 
concentration of 5 μg/ml for various periods, and an oxidative sensitive dye, 2’,7’,- DCFH-
DA was added at 5 μM during the last 15 minutes of incubation. DCFH-DA is nonfluorescent 
until oxidized by ROS. An increased DCF fluorescence indicates oxidation by peroxides, 
including hydrogen peroxide, hydroxyl radical and peroxynitrite. Samples were washed with 
FACS buffer and analyzed by FACS for fluorescence signals within the PI
- 
populations. 
 
Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) 
1.5x10
5
/ each 24 well iDCs were incubated for 5-6 hr with respective immobilized wells and 
supernatants were analyzed using specific ELISA detection Kits (BD biosciences). In brief, 
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100 μl of diluted capture antibody was added in maxisorb 96 well plate and incubated 
overnight at 4
o
C, after washings plates were blocked with 200 μl of block buffer 
(PBS+10%FBS) for 1 hr at RT. After adequate washings either standard or samples were 
incubated for 2 hr at RT. Finally the plate was washed and detected with the specific 
detection antibody conjugated to HRP. The absorbance of the plates was measured using 
ELISA-reader μ-Quant (Bio-Tek, Bad Friedrichshall, and Germany) in parallel with the 
measurement of the corresponding standards. 
 
Fluorescent Bead Immuno assay 
The bender med systems human Th1/Th2 11 plex assay was carried out according to 
manufacturer’s protocol. 
 
Soluble CD30 ELISA 
Flexible 96-well micro titer plates were coated with 100 μl of Ki-2 mAb (50 μg/ml in sodium 
carbonate buffer 50 mM, pH 9.2) for overnight incubation at 4
o
C. The plates were washed 3 
times with PBS + 0.05% Tween 20 (wash buffer) and subsequently blocked with PBS with 
10% FCS for 1 hr at RT. After triplicate washings, serial dilutions of sCD30 standard and test 
samples were added and incubated for 1 hr at room temperature. Plates were washed for 3 
times and incubated with 100 μl of peroxidase-coupled Ki-3 mAb for 1 hr at RT. The plates 
were further washed and detected with 100 μl of OPD substrate solution (Sigma Aldrich, St 
Louis, USA). After incubation the plates were evaluated at 492 nm using ELISA reader.   
 
CD30-Dependent Maturation of Dendritic cells 
DCs were collected on day 6 and cultured around 3x 10
5
 cells in 12 well coated with 5 μg/ml 
concentrations of different CD30-Ig constructs, in the presence of IMDM media for 36-48 
hours. The cells were harvested and checked for the surface expression of co-stimulatory 
molecules in FACS analysis.     
For the NK-DC co culture, iDCs were collected on day 5 and incubated with activated NK 
cells at 5:1 for 36-48 hours in medium (RPMI+5% FBS) at 37
o 
C and 5% Co2 .DCs were 
analyzed for maturation markers in flow cytometric analysis. Dendritic cells alone were used 
as the control for the co-culture experiments. 
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Confocal Microscopy 
Mo-DC (iDC or CD30 stimulated mature DC) and T cells were gently mixed at a ratio at 1:3 
and spread onto a slide coated with poly-D-lysine. Slides were incubated for 25 minutes a 
37
o
C. After incubation cells were washed with 1X PBS and fixed in 4% paraformaldehyde 
and permeabilized with PBS+0.5% Saponin (Wash buffer) for 30 minutes at room 
temperature. The cells were blocked for further 30 minutes in blocking buffer (wash buffer + 
3% BSA) and washed 3 times before immuno staining. Cells were stained with appropriate 
primary antibodies (e.g. anti-human CD3) diluted in wash buffer +1% BSA for overnight at 
4
o
C. Later, the slides were extensively washed and incubated with the specific secondary 
antibodies (e.g. Alexa 594) for 1 hour at room temperature. The nucleus was stained with 
Hoechst 33342 for 10 minutes at room temperature. The cells were finally washed with water 
and then mounted the slide with mounting medium (aqua poly/mount – Polysciences, Inc). 
Confocal stack images were obtained with a Zeises LSM 150 laser scanning confocal 
microscope using a 60X W 1.4 NA apochromat plan objective. Z-projection of slices and 
image analyses were performed using Zeises LSM image examiner software and Image J. 
The pictures were finally made using Adobe Photoshop. 
 
Proliferation assay by CFSE 
Principle: This method has been useful in determining cell division in B and T cells. The 
carboxyfluorescein diacetate succinimidyl ester (CFSE) passively diffuses into cells. It is 
colourless and non-fluorescent until the acetate groups are cleaved by intracellular esterases 
to yield highly fluorescent carboxyfluorescein succinmidyl ester. The succinmidyl ester group 
reacts with intracellular amines, forming fluorescent conjugates that are well retained and can 
be fixed with aldehyde fixatives.  
The dye-protein adducts that are formed in labelled cells are retained throughout 
development and meiosis. The label is inherited by daughter cells after either cell division or 
cell fusion, and is not transferred to adjacent cells in a population. 
 
Method: CFSE stock solution was prepared in DMSO according manufacture’s protocol 
(Molecular probes, Invitrogen). Resting T cells were resuspended with PBS+0.1%BSA at a 
final concentration of 1x10
6
/ml. The CFSE at 10 M final concentration was added to cells 
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and incubated at 37
o
C for 10 minutes. The cells were further incubated on ice for 5 min by 
addition of 5 volumes of ice-cold media. Cells were washed 3 times with fresh media and co-
cultured in different ratios with either iDC or CD30 stimulated DC and incubated at 37
o
C for 
5-6 days and measured for proliferation by flow cytometry at 488 nm (FL-1 staining). 
 
Stimulation of Granulocytes 
Freshly isolated granulocytes 1x10
6
/ml were incubated in the presence of sCD30 transfected 
or mock transfected or untransfected supernatants in the presence or absence of antiCD30 
antibody (HeFi-1) in serum free RPMI medium. After over-night incubation, supernatants 
were harvested and analyzed in IL-8 ELISA according to manufactures (BD Bio-Sciences) 
protocol. 
 
Time-lapsed video microscopy data analysis and cell tracking 
24 well plates were pre-coated with fibronectin at concentration of 10 μg/ml diluted in PBS 
for 1 hr at room temperature and washed twice with serum free medium. Freshly isolated 
granulocytes were seeded in wells and incubated for 30 minutes at 37
o
C to allow them to bind 
to the coated plates. Then, non-adherent cells were carefully washed out and 200 μl of 0.1% 
BSA+ 200 μl transfected supernatant was added. Blocking experiments were performed with 
either anti-CD30 antibody (HeFi-1) or isotype antibody at concentration of 3μg/ml. The 
surface of the medium was overlaid with 400 μl mineral oil to avoid evaporation. The 
migration of cells was recorded for 60 minutes in an incubator chamber attached to 1X81 
microscopes (Olympus Europa GmbH, Hamburg, Germany) at 37
o 
C, 5% Co2. For tracking, 
20-40 cells within the microscopic field of approximately 800600 m were randomly 
selected in each experiment and were analyzed using a computer-assisted cell tracking 
system. Frames were taken for every two minutes using an OBS CCD FV2T camera 
(Olympus). For visualization and quantification of cell movements, the computer programs 
OBS cell R (Olympus) and DIAS (Solltech.Oakdale, IA) were used. Individual cells are 
tracked based on similarities in brightness and shape. The directionality of an individual cell 
is defined as the distance between the start and end position of the cell. The locomotive 
pattern and moving speed were analyzed by drawing the trajectory of each cell using 
digitizer.  
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Trans-well assay 
24 well plates (3 μm pore size) were pretreated with 0.1% BSA and washed twice with RPMI 
media. The lower chamber was filled with 300 μl of 0.2% BSA+ 300 μl of transfected 
supernatants and the upper chamber contains 10
6
 granulocytes in 150 μl of RPMI+0.1% BSA. 
Plates were incubated at 37
o
C for 50 minutes and measured by trypan blue staining for the 
migratory cells in the lower chamber. 
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The results of all the cytokine release assays are indicated as means + standard deviation. 
Significance was calculated with Graph Pad Prism software (San Diego, CA) using student t-
test. Other software used are Microsoft Office, Adobe Photoshop, Win-MDI, Cyflogic and 
Image J. 
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Primer design and analysis, elementary DNA and protein sequence analysis were performed 
using DNA star. 
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10X PBS:  1.37 M   NaCl 
27 mM  KCl 
100 mM  Na2HPO4 x 2 H2O 
20 mM  KH2 PO4 
 
10X TBS:  1.37 M   NaCl 
27 mM  KCl 
248 mM  Tris Base 
 
FACS Buffer:  1x PBS +0.2% BSA+0.2% sodium azide. 
 
ELISA Buffers: Coating Buffer: 8.4 g NaHCO3 +3.4 g Na2CO3 in 1 liter, pH 9.5 
Dilution Buffer: 1xPBS+10%FBS 
Wash Buffer:  1xPBS+0.05% Tween 20 
 
FPLC column Buffers: 
Binding buffer: 50 mM Tris Base, pH 8.0 
Wash Buffer:  50 mM Tris Base, pH 8.0 
Elution Buffer: 100 mM Glycine+100 mM NaCl, pH 2.7 
 
Blot Buffers: 
PVDF Membrane:  3 g Tris Base 
14.4 g Glycine 
200 ml Methanol 
800 ml H2O 
Nitrocellulose Membrane: 250 mM Na2HPO4 
Wash Buffer:   1xTBS+ 0.1% Tween 20. 
 
Composition of Buffers 
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50X TAE Buffer: 2 M  Tris acetate 
50 mM EDTA (pH 8.0) 
 
LB Medium:  1%  Tryptone 
1%  NaCl 
0.5%  Yeast extract  
 
LB Medium:  1%  Tryptone 
(Low Salt)  0.5%  NaCl 
0.5%  Yeast extract 
Zeocin concentration 25 μg/ml 
 
LB agar:  LB medium + 1.5% Agar 
 
Transformation Buffers: 
TFB1   30mM  CH3COO Na 
   50mM  MgCl2x6H2O 
   10mM  CaCl2x2H2O 
   100mM NaCl  
   15%   glycerol  pH: 5.8 
TFB2   10mM  Mops 
   75mM  CaCl2x2H2O 
   10mM  NaCl 
   15%   glycerol  pH 7.0 
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The sources of cells were buffy coats acquired from healthy donors. PBMCs were separated 
by Ficoll-Plaque gradient centrifugation with Leucosep columns and were incubated 45 
minutes in plastic culture flasks (Nunc) at 37
o
C. Suspension cells were washed out and the 
adherent monocytes were allowed for differentiation in IMDM media containing IL-4 (20 
ng/ml) and GM-CSF (50 ng/ml) (Fig. 5A). 
The purity of immature dendritic cells was assessed after 5 days culture using FACS 
analysis. Immature DC were CD14
-
, CD1a
+
, CD80
+
, CD86
+
 and CD83
 -/very low
. As shown in 
Fig. 5B, only the cells were used that were 90-95% negative for CD14 and CD83, which are 
markers for monocytes and mature DCs, respectively. 
  
Figure 5: Generation of monocytes-derived dendritic cells. (A) Schematic representation of dendritic cell 
purification. (B) Surface phenotype of monocytes-derived immature dendritic cells. Non-adherent cells were 
stained for CD14, CD83, CD1a, CD80 and CD86 conjugated to fluorescent antibodies and analyzed by FACS. 
The relative cell count was kept constant on the Y-axis and the fluorescence was shown as histograms. The grey 
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histograms represent the antibody controls and the opened color histograms determine the surface expression of 
different markers. 
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The expression of CD30L is restricted to immune cells and tightly regulated. Previous studies 
showed that human immature dendritic cells express on their cell surface cytotoxic TNF 
family ligands (Lu et al. 2002) and recent studies also demonstrated that CD30L is up 
regulated on myeloid and plasmacytoid dendritic cells in mice upon inflammation (Zeiser et 
al. 2007). It was therefore tested whether human dendritic cells might express CD30L 
(CD153). The classical immature dendritic cells were generated from adherent monocytes, 
from PBMCs of healthy donors. Stimulation of immature dendritic cells with TNF-alpha for 2 
days, led to the maturation of DCs (mDCs). The CD30L expression on human DCs during 
differentiation was examined by RT-PCR and FACS analysis. The mRNA expression of 
CD30L was partially detectable during 3
rd
 day of monocyte-differentiation and was up 
regulated on 6
th
 day of differentiation (iDCs). In contrast, the CD30L mRNA expression was 
reduced in mDCs stimulated by TNF-alpha (Fig. 6A). The RT-PCR products correspond to 
the same size as the positive control (recombinant CD30L construct). The housekeeping gene 
GAPDH served as a control and confirmed equal synthesis of cDNA in all the cell types. In 
line with the mRNA expression, the surface expression of CD30L protein on Mo-iDCs is 
present and reduced on TNF alpha-mDCs as demonstrated by mean fluorescence intensity 
(MFI) using flow cytometry (Fig. 6B). Consistent to the previous studies the expression level 
of co-stimulatory receptors CD80, CD83 and CD86 was up regulated upon maturation and 
the detection level of the controls (antibody and CD14) was not affected (Fig. 6B).  
In addition, a representative histogram of CD30L expression on the surface of iDCs 
was obtained by FACS analysis, where cells were stained with isotype and CD30-ligand 
antibody and detected with PE-conjugated goat anti-mouse antibody, measured in FACS 
calibur (BD Biosciences) (Fig. 6E). Moreover, the surface expression was also determined by 
microscopy. For microscopy analysis, Mo-iDCs were stained with monoclonal antibodies 
anti-human CD30L and corresponding isotype followed by detection with the specific 
secondary antibody rabbit anti-mouse conjugated to Alexa-594. All the nuclei were stained 
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with Hoechst 33342 (Fig. 6C). Analysis of the cell lysates by western blotting with specific 
antibody also revealed the protein expression (Fig. 6D). 
 
Figure 6: Expression of CD30L on monocyte-derived DCs. (A) Human iDCs were differentiated from 
adherent monocytes in presence of GM-CSF and IL-4 for 6 days. Mature DCs were generated from iDCs by 
stimulating with (20 ng/ml) TNF-alpha for additional 2 days. The expression of CD30L mRNA was assessed by 
standard RT-PCR. GAPDH was used as a control over the same period. M: marker, +: positive control for 
CD30L, 3: 3
rd
 day, 6: 6
th
 day (iDC), Mat: mature DCs (TNF-alpha). (B) iDCs (shaded bars) and mature DCs 
(squared bars) were analyzed for surface expression of CD14, CD83, CD80, CD86 with conjugated antibodies 
and un-conjugated CD30L mAb followed by staining with PE goat anti-mouse Fab. Neg: cells alone, Control: 
Isotype antibody for CD30L. The mean fluorescence intensity (MFI) on the Y-axis was represented in two 
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segments and the segment 65-130 represents for only CD86. (C) CD30L surface expression was shown by 
histogram analysis. Gray shaded histogram represents the isotype antibody; and open histogram represents 
staining of CD30L. (D) iDCs were stained with isotype antibody (left), or anti-CD30L (right). Blue color 
represents the nucleus staining and red color indicates the CD30L specific antibody detection. (E) iDC lysate 
was checked for protein expression by western blot analysis. 10 μg/ml of iDC lysate was loaded in 10% SDS 
PAGE gel and detected with mAb for CD30L. 
Next it was investigated whether freshly isolated peripheral blood DCs express 
CD30L. Blood DCs were purified and isolated from PBMCs of healthy donors using positive 
selection by MACS separation. The expression of CD30L on human blood DCs was 
determined by RT-PCR and FACS analysis. The purity of the cells was assessed by flow 
cytometry as CD14
-
, CD1a
+
. As shown in Fig. 7A, specific amplified products were clearly 
detectable demonstrating the presence of CD30L mRNA in blood DCs. To determine whether 
transcription of the CD30L was accompanied by specific protein expression in blood DCs, 
the cells were stained with anti-CD30L and were analyzed by flow cytometry (Fig. 7B). 
Taken together, CD30L is expressed on DCs. 
 
 
Figure 7: Expression of CD30L on blood-derived DCs (A) Blood DCs were purified from PBMCs using auto 
MACS and the expression of CD30L mRNA was determined by RT-PCR. Lane 1: CD30L construct, positive 
control, lane 2 is CD30L expression, lane 3: GAPDH control and last lane M is Marker. (B) Surface expression 
of CD30L on blood iDC was analyzed by flow cytometry. Shaded grey region is isotype control and opened 
histogram (blue) shows the CD30L expression. 
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The ectodomain of CD30 and deleted portions thereof were generated as human-Ig fusion 
proteins. The DNA constructs were analyzed by sequencing either with T7 promoter or gene-
specific forward primers. In this study, the constructs were labeled as LCD30 (entire 
ectodomain containing domain 1 to 6 and stalk), MCD30 (domain 1-2-6 and stalk), SCD30 
(domain 1 and 6 and stalk), D1-2CD30 (domain 1-2 and stalk), D1CD30 (domain 1 and stalk) 
and D6CD30 (domain 6 and stalk). Figure 8A shows the schematic representation of the 
constructs. The CD30-Ig constructs were expressed in 293T cells by transfection with 
specific cDNAs using lipofectamine (Invitrogen). After transfection the supernatants were 
collected twice for every 48 hours. An affinity column with Protein-A sepharose beads (GE) 
was used to purify the Ig-proteins from the harvested supernatant on HPLC instrument (Bio-
Rad). The purified proteins were dialyzed against PBS and sterilized by filtration. The 
concentrations of proteins were determined by bicinchoninic acid-based protein assay 
(Pierce). The purified CD30-Ig proteins were also analyzed by Coomassie brilliant blue 
staining after SDS/PAGE analysis (Fig. 8B). The specificity of the human-Ig was 
demonstrated by western blotting using anti-human Ig antibody (gamma-specific antibody) 
and followed by HRP-conjugated secondary antibody (Fig. 8C). This showed the expression 
of CD30 ectodomain variants fused with the Fc-portion of human-Ig. Additional bands of 
lower molecular weight were observed in Coomassie as well as in western blot; they probably 
represent traces of the degraded proteins. In summary recombinant-Ig constructs were 
expressed, purified and feasible for the further functional experiments. 
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Figure 8:  Construction and expression of CD30-Ig fusion proteins. (A) Schematic representation of CD30 
Ig constructs. CD30-Ig variants were purified from the supernatant of 293T-transfected cells and stained with 
Coomassie brilliant blue (B) and immuno-blotting (C) as indicated. In immunoblot proteins were detected by 
goat anti-human anibody, followed by anti-goat HRP antibody. 
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8.4.1. FACS Analysis:  
To study the effect of CD30 on DCs, monocyte-derived iDCs were stained with CD30-Ig. To 
identify the specific domain that binds to iDCs, all tested proteins, were dialyzed against 
PBS. Proteins were incubated on ice at 10-μg/ml for 40 minutes to allow binding to CD30L 
positive iDCs and the fusion constructs were detected with FITC-conjugated anti-human Ig 
(Ig-gamma specific) using FACS analysis. The mean fluorescence intensities determined by 
FACS analysis, indicated that the constructs LCD30, MCD30, SCD30 and D1-2CD30 
interact with DCs albeit with different intensity. Staining with the constructs D1CD30 
(domain 1 alone) and D6CD30 (domain 6 alone) did not notably interact with Mo-iDCs (Fig. 
9), this demonstrates specificity of the binding of CD30 constructs L, M, S and D1-2.   
  
Figure 9: Interaction of CD30-Ig variants to iDCs. The mean fluorescent intensity (MFI) on Y-axis 
determines the strength of binding. 
 
8.4.2. Pull-down Assay 
To demonstrate binding of CD30L to recombinant CD30-Ig, the in-vitro interaction was 
further investigated in an independent assay using pull-down experiments. CD30-Ig 
constructs were purified from mammalian cells and used as soluble proteins. CD30L was 
produced as GST fusion protein. GST alone (control protein) and GST-CD30L was expressed 
in E. coli and purified as recombinant proteins possessing an N-terminal Glutathione-S-
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Transferase (GST) tag. The GST fusion proteins were immobilized on glutathione-Sepharose 
beads to pull down the specifically interacting proteins. As shown in the Fig. 10, immobilized 
GST-CD30L was able to pull down LCD30, MCD30 and SCD30 whereas the control protein, 
immobilized GST did not pull-down any of the CD30-Ig constructs. GST-CD30L pull-down 
of CD30-Ig was detected when performed under non-reducing conditions. The above data 
indicate that under non-reducing conditions the disulphide bridges were intact between the 
cysteine residues present in the extra-cellular domain of CD30. This further suggests that the 
interaction between CD30-CD30L also depends on the cysteine-rich domains (CRD). 
Probably as mentioned for other TNF receptors like TNFR1, the CRDs in the ectodomain of 
CD30 could also enable the formation of trimeric structure that binds to its cognate ligand. 
The above interaction data imply that at least two CRD domains of CD30 (TNF-
receptor) are required for binding to CD30L (TNF ligand). Therefore, CD30L could bind to 
LCD30-Ig, MCD30-Ig, SCD30-Ig and D1-2CD30-Ig but not to the constructs with only one 
CRD domain (D1CD30-Ig and D6CD30-Ig). 
 
Figure 10: Pull-down assay. GST-CD30L and GST were immobilized on Glutathione Sepharose beads and 
incubated at 4°C with 10μg/ml of LCD30-Ig, (15 minutes), MCD30-Ig (15 minutes) and SCD30-Ig (90 minutes) 
to assess their ability to pull down CD30 variants. Beads were thoroughly washed with buffer and were boiled in 
SDS-PAGE non-reducing sample buffer and the solubilized proteins were resolved on 10% polyacrylamide gels. 
The pulled-down of LCD30-Ig and MCD30-Ig was detected using Ber-H2 and SCD30-Ig was detected by Ki-2 
antibody, followed by incubation with anti-mouse HRP and then analyzed by immuno-blotting. 200 ng of 
purified protein was loaded as input. Interaction of CD30L is seen with CD30 variants, whereas GST alone does 
not show any interaction. 
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Interaction of receptor and ligand does not mean function; therefore, a series of functional 
experiments was performed. The biological functions were mainly dependent on cytokines 
secreted from different immune cells. Dendritic cells are a major source of many cytokines, 
which are important in the elicitation of primary immune response (Zhou and Tedder 1995; 
Cella et al. 1996). Moreover, the effect of CD30-mediated bi-directional signaling of 
CD30L+ cells was described for other cell types like mast cells and neutrophils (Wiley et al. 
1996; Molin et al. 2001). Therefore, the physiological cytokine release was tested from Mo-
iDCs, stimulated with immobilized different CD30-Ig constructs, using Th1/Th2 11-plex 
analysis. Interestingly, we could observe pro-inflammatory cytokines TNF-alpha, IL-6 and 
IL-8 from DCs, when stimulated with LCD30-Ig, MCD30-Ig and D1-2CD30-Ig, whereas 
control-Ig did not show any effect (Fig. 11). There are no detectable levels of these cytokines 
in the presence of SCD30-Ig, D1CD30-Ig and D6CD30-Ig. Even though SCD30-Ig binds to 
DCs (Fig. 9) it did not have any functional importance in the release of cytokines except for 
IL-8 release. Intriguingly, we did not find any release of other cytokines like IFN-gamma, IL-
1b, IL-2, IL-4, IL-5, IL-12 (p70), and TNF-beta and IL-18. IL-10, an anti-inflammatory 
cytokine is also released from DCs in minute amounts (2-8 pg/ml) with the effect of MCD30-
Ig and D1-2CD30-Ig, suggesting a role in inhibiting the synthesis of some pro-inflammatory 
cytokines as mentioned above. The cytokine release stimulated with MCD30-Ig and D1-
2CD30-Ig was consistent among other constructs. Since, MCD30-Ig is closer to the real 
native structure of CD30 ectodomain; it was used for further experiments. 
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Figure 11: Pro-inflammatory 
cytokine release from iDCs upon 
stimulation with CD30-Ig variants. 
Mo-iDCs were stimulated with 5 
μg/ml of either CD30-Ig variants or 
control-Ig for 2 days at 37
o
C and the 
supernatants were collected. Specific 
inflammatory cytokines like TNF-
alpha, IL-6, IL-8 and IL-10 were 
analyzed in the supernatants using 
Th1/Th2 11-plex kit (Bender 
MedSystems). This method was 
performed using flow cytometry. The 
final concentrations were calculated 
in pg/ml using software designed for 
this assay (Flow Cytomix Pro 2.2). 
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With relevance to the function of MCD30-Ig function, a striking phenomenon was observed 
that MCD30-Ig is better stimulant than LCD30-Ig. Probably the antibody construct LCD30-Ig 
(the entire extra-cellular domain), do not represent the physiological CD30 at the cell surface 
due to dimerization, forming a complex structure with human Ig. This could bind and 
stimulate CD30L cells (iDCs), but in an in-consistent manner. In contrast, MCD30 is 
comprised of three CRDs of the extra-cellular domain, resembling to other TNF receptors. It 
is also similar to the functional CD30 homologues of mouse and rat in domain structure. 
Thus, MCD30 when fused with human-Ig and immobilized would better represent the native 
structure of CD30. Therefore and because of the best activity of this construct, it was 
dominantly used in subsequent experiments. 
 To obtain a better insight for the future experiments, the other important aspect to be 
mentioned is the correlation of CD30-specific antibody binding sites with the knowledge of 
CD30L binding sites. Several groups have taken up the task to characterize the relationships 
among epitopes recognized by different anti-CD30 MAb using cross-blocking approaches. 
Based on patterns of mutual inhibition, anti-CD30 MAbs have been assigned to one of the 
three cluster groups (A, B, and C). Franke and his group determined in detail that MAbs 
belonging to cluster C (e.g. HeFi-1 and M44) effects the biological effects on CD30 by 
blocking CD30L mediated effect and to a little extent with MAbs of cluster A (e.g. Ki-4 and 
Ber-H2).  The antibodies of cluster B (Ki-1) do not block the effect of CD30L (Franke et al. 
2000). Therefore, in subsequent related experiments, HeFi-1 (cluster C) was used for 
blocking the cross-linking effect of CD30-CD30L on immature dendritic cells and Ki-1 
(cluster B) was used as control antibody. 
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In addition to the previous binding experiments, interaction of MCD30-Ig to immature 
dendritic cells was further confirmed by staining with a specific anti-CD30 antibody (Ki-1) 
conjugated to FITC. It was observed that MCD30-Ig binds strongly to Mo-iDC surface 
compared to the control-Ig (Fig. 12A). Since, the cytokine release stimulated with MCD30-Ig 
was consistent; a detailed study of this functional interaction was performed. A robust 
secretion of the pro-inflammatory cytokines TNF-alpha, IL-6 and IL-8 was observed in 
response to MCD30-Ig stimulation (Fig. 12B). Control-Ig was used as a negative control. 
This stimulation was specific for CD30L-CD30 interaction, since it was inhibited by anti-
CD30 antibody HeFi-1 (cluster C), known to disrupt the CD30-CD30L interaction (Franke et 
al. 2000). Ki-1 (cluster B) is a specific antibody against CD30 does not have any effect on 
functional interaction. This was used as control and did not have any inhibitory effect. 
 
Figure 12: MCD30-Ig specifically induces the cytokine release from Mo-iDCs. (A) The histogram shows 
binding of MCD30-Ig on iDC surface as detected by CD30 specific antibody. Shaded grey region shows the 
anti-CD30 antibody alone (Ki-1 conjugated to FITC). Green color overlay indicates binding of control-Ig and 
red color overlay determines the MCD30-Ig binding as detected by Ki-1 FITC. (B) Blocking of CD30-CD30L 
interaction inhibits the release of pro-inflammatory cytokines. Immobilized MCD30-Ig was blocked using 10 
Results 
 
μg/ml concentration of anti-CD30 antibodies either Ki-1 or HeFi-1 and simulated with Mo-iDC for 6 hr at 37oC. 
Supernatants were analyzed for specific cytokine specific ELISAs. Neg: DC alone, Ig: Human-Ig control. The 
quantity of cytokines released was determined as pg/ml. The data shown is for one representative experiment 
among three experiments. 
 
Next, the specific cytokine release was further determined by checking the dose- 
dependent production of pro-inflammatory cytokines by DC in response to MCD30-Ig. Mo-
iDC were incubated with immobilized MCD30-Ig at concentrations ranging from 10 μg/ml – 
0.312 μg/ml. Culture supernatants were assessed for the production of TNF-alpha, IL-6 and 
IL-8 by cytokine specific ELISA. Stimulation of Mo-iDCs with MCD30-Ig resulted in a 
dose-dependent increase in the production of the cytokines TNF-alpha, IL-6 and IL-8 (Fig. 
13). The optimal induction of TNF-alpha, IL-6 and IL-8 by MCD30-Ig was observed at a 
concentration of 5 μg/ml, whereas the control human-Ig did not show any dose-dependent 
increase effect. Taken together, the results demonstrate a functional pro-inflammatory 
response of iDCs mediated via CD30-CD30L interaction. 
 
 
 
 
Figure 13: Dose-dependent release of cytokines by iDCs in response to MCD30-Ig. Monocyte-derived iDC 
(3x10
5
/ml) were stimulated with various concentrations of immobilized MCD30-Ig and human-Ig. Culture 
supernatants were harvested after 20 hours and assessed for TNF-alpha, IL-6 and IL-8 levels by ELISA. Results 
are expressed as the mean +/- SD of duplicate cultures from one of three representative experiments. 
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The up-stream mechanisms or signaling events were further analyzed to elucidate the release 
of different pro-inflammatory cytokines from iDCs upon stimulation with CD30 on the 
molecular level. ROS is a key element of the innate immunity that acts as an intracellular 
secondary messenger and activates MAP-kinase pathway which in turn initiates specific 
biological functions such as proliferation, differentiation, apoptosis and cytokine production 
(Kim and Ro 2005). Previously, it has been described that upon CD30-Ig stimulation, ROS 
was generated in neutrophils and also enhanced the release of IL-8 (Wiley et al. 1996). It was 
therefore tested; with the stimulation of CD30 whether iDCs produce oxidative burst (ROS) 
and has a role in MAP kinase-dependent cytokine release. 
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To test for the generation of ROS, control human-Ig and MCD30-Ig were immobilized as a 
mimic of membrane anchored proteins and phorbol 12-myristate 13-acetate (PMA) was used 
as positive control to stimulate monocyte-derived iDCs at different time intervals. Using flow 
cytometric analysis, the intracellular ROS levels were monitored by adding 2’, 7’-dichloro 
fluorescin diacetate (DCFH-DA) at the end of the incubation period. This cell permeable 
probe shows intracellular deacetylation and becomes highly fluorescent upon oxidation by 
hydrogen peroxide. Fig. 14 demonstrates that small amounts of ROS were generated after 3 
minutes; they increased after 7 minutes and decreased at later time points for both positive 
control (PMA) and with MCD30-Ig. The generation of ROS was absent with the negative 
control human-Ig demonstrating a CD30 specific ROS in iDC. This proves that engagement 
of CD30L with MCD30-Ig activates ROS signaling in DCs. 
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Figure 14: ROS from Mo-iDC induced by cross-linking of CD30L in a time-dependent manner. Monocyte-
derived DCs were stimulated with immobilized MCD30-Ig or control human-Ig for indicated times. After end of 
incubation period, cells were loaded with 5 mM 2’,7’ Dichlorofluorescin-diacetate (DCFH-DA) for further 15 
minutes. Cells were washed and immediately the oxidation of DCFH-DA dye was measured by FACS. PMA 
(30 ng/ml) was used as a positive control. Gray background: stimulation with control Ig, Red: MCD30-Ig, Blue: 
PMA stimulation. The generation of ROS was determined by counting 10,000 cells, and the histograms were 
processed by Win-MDI program. One representative experiment of three is shown. 
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Previous reports suggest that the MAP-kinase pathway is stimulated in response to ROS 
generation and could finally result in cytokine expression. To unravel the contribution of the 
MAP-kinase pathway in CD30-specific cell activation, Mo-iDCs were stimulated with 
MCD30-Ig in the presence of specific MAP kinase inhibitors. The pro-inflammatory cytokine 
TNF-alpha level was specifically up regulated by CD30-Ig and failed after triggering with 
control human Ig. Not only CD30-dependent but also the constitutive release of TNF-alpha 
was inhibited by PD98059 (50 M), SB203580 (10 M) and SP100625 (10 M) targeting 
extra-cellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK), 
respectively (Fig. 15). TNF-alpha release from Mo-iDCs also involved the MAP kinase 
pathway, even when stimulated with bacterial LPS or PMA. The data demonstrate that 
ligation of CD30L on iDCs generates oxidative burst and stimulates pro-inflammatory 
response mediated by MAP-kinase pathway. 
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Figure 15: Effects of specific MAPK inhibitors on the production of TNF-alpha. Mo-iDCs were stimulated 
with 5 μg/ml human-Ig (control), or MCD30-Ig, for positive control 30 ng/ml of PMA and 1 μg/ml of LPS was 
used. MAP kinase inhibitors (SB203580 for p38; SP600125 for c-Jun-N-terminal kinase-c-JNK; PD98059 for 
extracellular signal -regulated kinase-ERK) were added 10 minutes before the simulation. Supernatants were 
collected after 6-hr incubation and analyzed in TNF-alpha ELISA. Cells were not stimulated: Neg. 
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Recently, several studies have shown that interactions between DCs and NK cells result in 
cytokine secretion and maturation of iDCs leading to a proper immune response. Previous 
studies describe an important role for TNF-alpha in inducing maturation of DCs upon co-
culturing with activated NK cells (Ferlazzo et al. 2002; Gerosa et al. 2002). Upon stimulation 
with CD30-Ig a specific release of TNF-alpha was observed. Therefore, I could hypothesize 
that CD30 on NK cells also might have a physiological significance on CD30L-mediated DC 
maturation. Primarily, the expression of CD30 receptor was analyzed by FACS analysis on 
polyclonal NK-cell populations or clones after limiting dilution NK cell clones. 
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To obtain polyclonal populations, NK cells were purified from PBMCs of healthy donors and 
cultured for 7-10 days in presence of recombinant IL-2 (150 U/ml) and 5 μg/ml phyto-
hemagglutinin (PHA). The NK-cell populations were assessed for purity, and only those 
homogenously expressing NKp46 of classical NK cells were gated to analyze the expression 
of CD30. The NK-cell phenotype was determined using different NK cell markers CD56, 
NKp46 and NKp30. It was described that NKp44; a natural cytotoxicity receptor, is 
expressed exclusively on activated NK cells. CD30 is also expressed on polyclonal activated 
NK cells as demonstrated by staining with CD30 specific antibody (Ki-1) conjugated to 
phycoerythrin (Fig. 16). 
 
Figure 17: Surface expression of cultured activated NK cell markers. Activated NK cells were stained with 
indicated anti-NK cell antibodies (PE-coupled anti-NKp46, FITC-coupled anti-CD56, PE-coupled anti-NKp30, 
PE-coupled anti-NKp44 and PE-coupled anti-CD30), then gated for CD3
-
 NKp46
+
 (NK cells) and analyzed by 
flow cytometry. Cells, not stained with antibody are demonstrated in filled histograms. The opened overlaid 
histogram shows the specific antibody staining.   
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Primary NK cells were purified as described and activated with rIL-2 and PHA for 3-4 days. 
NK-cell clones were obtained by performing limiting dilutions of the activated NK cells in 
presence of high concentrations of IL-2 (100-200 U/ml) for 2 weeks co-cultured with 
irradiated PBMCs (2000 Rad). NK-cell clones obtained were NKp46 positive (90%) and very 
few clones are CD3+ (5-10%). As described earlier, CD30 expression was analyzed on the 
cells with NKp46 phenotype by FACS analysis. Expression of CD30 on such clones was not 
uniform but differentially expressed as demonstrated by the scattered distribution of cell 
fluorescence intensity (Fig. 17). The expression of CD30 ranged from 18% to 55% and few 
clones being completely negative. Intriguingly, even though all the clones were 85-95% 
NKp46
+
, it is still unclear why there is a difference in CD30 expression. For further 
experiments, I have used polyclonal NK cell populations and recombinant CD30 constructs to 
understand its role in NK-DC interaction. 
 
Figure 17: Distinct expression of CD30 on NK clones. Freshly isolated NK cells were purified and cultured 
for 3 weeks in the presence of the irradiated PBMCs. The obtained NK clones were analyzed by two-color 
immunofluorescence for the expression of NKp46 and CD30. Anti-NKp46 antibody was APC-labeled and anti-
CD30 antibody was labeled with PE. Dot plot shows the percentage of CD30
++
 NK cells for four different NK 
clones. 
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As a proof of principle, co-culture of CD30-positive NK cells and iDCs (ratio 1:5) resulted in 
the up-regulation of the co-stimulatory molecules CD80 (Fig. 18A) as determined by flow 
cytometry. This induction declined upon addition of anti-NKp30 antibody, since it was 
described as the major triggering receptor for DC maturation (Vitale et al. 2005). Interstingly, 
a similar inhibitory effect was also observed with anti-CD30 antibody (HeFi-1), indicating a 
physiological role of CD30/CD30L-signaling for the maturation of iDCs. Supporting, the up-
regulation of co-stimulatory receptors CD80 and CD86 on mature DCs was also estimated by 
the median values obtained by FACS analysis. The data represents the involvement of CD30 
in maturation of iDCs as shown by blocking with anti-CD30 Ab (HeFi-1) compared to 
control antibody (Fig. 18B). However, the expression was not completely abolished, probably 
reflecting to the contribution of receptors distinct from CD30 such as NKp30 and NKG2D on 
NK cells (Moretta 2002; Vitale et al. 2005). 
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Figure 18: Blocking of CD30 inhibits the up-regulation of co-stimulatory markers in NK-DC co-culture. 
(A) Immature DCs were co-cultured with allogenic polyclonal activated NK cells for 2 days in the absence or 
presence of with anti-NKp30 mAb or anti-CD30 mAb (HeFi-1). DCs were analyzed for expression of CD80. 
Filled grey histogram indicated the CD80 expression of immature dendritic cells, and green color open 
histogram shows the iDC co-cultured with activated NK cells. Blue color open histogram represents the 
inhibition of maturation by anti-NKp30 antibody where as anti-CD30 antibody is red color histogram. (B) NK-
mediated DC maturation was also analyzed for the expression of CD80 and CD86. Monocyte-derived DCs were 
co-cultured with activated NK cells for 2 days in the presence or absence anti-CD30 antibody (HeFi-1) or 
isotype control (IgG1) at a concentration of 10 μg/ml. The data are expressed as the median values of CD80 and 
CD86 positive cells. ** P < 0.005, *** p < 0.0005 compared with isotype control. 
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The physiological state of DCs are believed to be strictly regulated by extra-cellular stimuli, 
including cytokines, adhesion/co-stimulatory molecules, and bacterial products. The 
activation and maturation state of DCs are correlated with morphological, phenotypical, and 
functional changes including up-regulation of cell surface molecules, migratory capacity, 
antigen uptake, processing capacity and T-cell stimulatory capacity. 
To analyze the effect of maturation more specifically, I directly tested whether engagement of 
CD30L was able to induce maturation of Mo-iDCs. Mo-iDCs were stimulated with 
immobilized MCD30-Ig (5 μg/ml), human-Ig as a negative control or TNF-alpha (20 ng/ml) 
as a positive control. After 48 hours, the cell surface expression of co-stimulatory receptors, 
indicating the maturation state of DCs, was analyzed by flow cytometry. Stimulation with 
TNF-alpha and MCD30-Ig induced an increase of the co-stimulatory molecules CD83, CD80 
and CD86, whereas a control-Ig did not affect Mo-iDC maturation (Fig. 19A). Thus, the data 
Results 
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are in line with CD30-dependent cytokine release (TNF-alpha and IL-6) from iDCs and the 
cells undergo the process of maturation by an autocrine mechanism, mediated specifically by 
MCD30-Ig.  
In another set of experiments, the maturation of Mo-iDCs was also performed by 
immobilized CD30-Ig variants. As shown in Figure 19B, the median values of the CD83, 
CD80 and CD86 expression were demonstrated. As expected, the up-regulation of CD83, and 
co-stimulatory molecules CD80 and CD86 were observed in the presence of LCD30, 
MCD30, and D1-2CD30, whereas SCD30 and D1CD30 and D6CD30 had no effect. 
Interestingly, CD86 expression was increased even when stimulated with SCD30, D1CD30 
and D6CD30. Control-Ig was always equal to the value of iDC alone. Thus, the specific 
function on maturation of iDCs with different CD30-Ig variants was consistent with the 
release of pro-inflammatory cytokines.  
Previous studies showed that DC maturation, induced by TNF-alpha, is correlated 
with cluster formation (Sato et al. 1999). Therefore, I examined the relationship between 
maturation of monocytes-derived DCs and their cluster formation. Results from light 
microscopy revealed that stimulation of DCs by different immobilized CD30-Ig constructs 
showed variation in their morphology when compared to iDC alone and control-Ig protein 
(Fig. 19C). The aggregation of DCs, upon CD30 stimulation directly correlated to the 
maturation of DCs. Thus these results indicate that CD30 stimulation changes the properties 
of monocyte-derived DCs in terms of morphology and phenotypic features. 
Results 
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Figure 19: Phenotypic maturation of DCs, induced by ligation of CD30-Ig. (A) Immature dendritic cells 
were harvested at day 6, incubated in GM-CSF, IL-4 free medium with 5 μg/ml of immobilized MCD30-Ig or 
human-Ig and for positive control 50 ng/ml of recombinant TNF-alpha were added. After 2 days cells were 
collected and stained with CD83, CD80 and CD86 using FACS analysis. Filled Grey histogram: human-Ig, 
Blue: TNF-alpha, Red: MCD30-Ig (B) Monocyte-derived dendritic cells were stimulated with immobilized 
CD30-Ig variants, median values of CD80, CD83 and CD86 expression was depicted as bar graphs. (C) Effect 
of CD30-Ig variants on the aggregated cluster formation of iDC. Mo-iDC (3x 10
5
) per well were untreated or 
treated with human-Ig or CD30-Ig variants for 2 days at 37
o
C. Magnification (10X) images were obtained by 
light microscopy. The results are representative of three experiments. 
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Encounter of cognate MHC complexes on the surface of antigen presenting cells (APCs) by T 
cells triggers the assembly of specialized structure at the APC-T cell interface, known as the 
immunological synapse (IS). This process involves the reorganization of membrane and 
intracellular signaling molecules in the T cell, leading to polarization of its secretory 
machinery toward the APC (Revy et al. 2001; Muller et al. 2006). This event is necessary for 
efficient T cell activation and function. An important morphological parameter associated 
with IS assembly is the polarization of the surface molecules in T cells. To this end, I 
investigated whether CD30 stimulated dendritic cells have some effect in formation of 
immunological synapse using confocal microscopy. When activated T cells were co-cultured 
with either allogenic iDC or MCD30-Ig stimulated DC (Mature DC), the CD3 expression on 
T-cells was not clustered to one region in the case of iDC alone, stating that polarization did 
not occur, whereas in the case of mature DC, CD3 expression was concentrated to one point 
at the site of IS, proving the point that the T-cell is polarized for a proper immune response 
(Fig. 20). But this effect was not observed with resting T cell and DC co-culture experiments. 
CD30-CD30L interaction contributes to DC-maturation and is sufficient to trigger their T-cell 
activation potential.  
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Figure 20: MCD30-Ig simulated-DCs are involved in allogenic DC-T cell IS. Monocyte- derived immature 
DC (iDC) or MCD30 stimulated mature DCs (mDC CD30) were co-cultured with allogenic T cells either resting 
or activated (1 μg/ml PHA for 24 hr) for 25 minutes. Cells were settled on to poly-L-lysine-coated slides, fixed, 
and stained for CD3, followed by goat anti-mouse Alexa 594-labeled secondary antibody (red color), Nucleus 
was detected by Hochest 33342 (blue colour). Polarization of T-cell was determined by confocal microscopy. 
Corresponding Nomarski merged images are shown on the right. Confocal Z-stacks images 0.4 μM were taken 
using 60X objective lense. 
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Mature DC displays an extraordinary capacity to stimulate the proliferation of naïve T cells. 
To evaluate whether MCD30 stimulated mature DC has the same effect or not, proliferation 
assays were performed with allogenic total T cells and isolated CD4+ or CD8+ cells. First, 
iDCs were stimulated with immobilized MCD30-Ig for 2 days to induce maturation. These 
cells were subsequently co-cultured with allogenic total T cells at different ratios. After 6 
days of co-culture the cells were gated for CD3
+
CD4
+
 or CD3
+
CD4
-
 and cell proliferation 
was determined by using carboxy-fluorescein diacetate succinimidyl ester (CFSE) staining. 
T-cell proliferation was observed when stimulated with mature DCs (stimulated with 
MCD30-Ig) compared to iDCs (Fig. 21). Although I observed the proliferated cells in all 
ratios of DC: T cells, the strength of T-cell proliferation in 1:1 ratio was less compared to 1:3 
or 1:5. Thus, the data together represent an indirect effect on T-cell function by CD30 during 
inflammation mediated by Natural Killer cells. 
 
 
Figure. 21: Mature DC (MCD30) promotes T cell proliferation in T-DC co-cultures. Immature DC (iDC) or 
MCD30 stimulated DC (mDC-CD30) were co-cultured with CFSE labeled T cells at different ratios like 1:1, 1:3 
and 1:5; at day 6 cells were harvested and stained for CD3 percp CD4 APC antibodies and analyzed by FACS. 
T-cells were gated for either CD3
+
and CD4
+
 or CD3
+
and CD4
- 
cells and the percentage of proliferated T-cells 
for both iDC and mDC-CD30 was determined. 
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As introduced, the function of the interaction of TNFR-TNFR ligand family members in 
immune regulation is not only regulated by cell-cell contact but also mediated by soluble 
factors. This includes cytokines (chemokines, lymphokines or monokines) but also soluble 
counterparts of TNFR and TNFRL family members (Armitage 1994; Croft 2003). However, 
in this context, the physiological function of CD30-CD30L interaction and a possible role of 
the soluble molecules are far from being understood. Following this interaction there is not 
only signaling through CD30 receptor but also through membrane anchored CD30L. It was 
previously described that contact-dependent reverse signaling of CD30L
+
 cells by 
recombinant CD30 (immobilized) results in the release of inflammatory cytokines like IL-8 
from mast cells, eosinophils and neutrophils (Wiley et al. 1996; Molin 2004; Fischer et al. 
2006). The previous sections describe the importance of CD30-CD30L interaction in the case 
of normal acute single-phase inflammation, playing a major role in the release of pro-
inflammatory cytokines and in NK-DC cross talk that leads to the maturation of DCs. 
The extra-cellular domain of CD30 is cleaved from the surface of CD30
+
 cells by the 
action of cell surface metalloproteinase TNF-alpha converting enzyme (Hansen et al. 2000), 
and binds to CD30L
+
 cells (Hargreaves and Al-Shamkhani 2002). Several reports 
demonstrated elevated levels of sCD30 in chronic inflammatory cases such as HL and ALCL, 
autoimmune disorder RA and skin disorder AD. Elevated serum levels of sCD30 in the 
majority of HL patients were associated with a poor clinical outcome. Therefore, it was very 
interesting to question whether sCD30 might also play a role in reverse signaling of 
CD30L+ 
+
 cells. 
In my preliminary experiments, the stimulation of iDCs with sCD30 resulted in the 
elevated levels of IL-10, an anti-inflammatory cytokine (Fig. 22). This result supports the 
observation that in RA, there is a direct correlation to the elevated levels of sCD30 and IL-10 
(Gerli et al. 2001). Moreover, sCD30 stimulated iDCs do not undergo the process of 
maturation, in contrast to the data shown for immobilized CD30. Since granulocytes are the 
most abundant immune cells in the milieu of Hodgkin’s tissue, this section describes the 
effects of sCD30 on granulocytes (eosinophils and neutrophils). 
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Figure 22:  sCD30 induces higher levels of IL-10: Mo-iDCs were stimulated with the purified sCD30 (5000 
units/ml)  using NHS-activated column loaded with anti-CD30 (Ki-2) column or by isotype column as a control 
(used same volume) and the supernatants were subjected to IL-10 ELISA. Neg: DCs alone. 
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CD30L expression has been reported on different immune cells and granulocytes are the 
major cells that play crucial role in innate system. It has been reviewed controversially that 
the expression analysis of CD30L on these cells was due to non-specific binding of antibodies 
and lack of controls (Kennedy et al. 2006). Thus, as one step behind, the cell surface 
expression of CD30L on granulocytes was analyzed on the mRNA and protein level. 
Granulocytes (polymorph nuclear leukocytes-PMN) were purified from whole blood obtained 
from healthy donors. The schematic representation of granulocytes isolation is shown in Fig. 
23. The isolation and purity of the granulocytes were confirmed by Pappenheim-staining 
method (Fig. 23). Staining of multi-lobed nucleus determines the characteristic feature of 
granulocytes. 
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Figure 23: Schematic representation of granulocyte isolation. The purple color multi-lobulated nuclei of 
granulocytes were determined by Pappenheim staining. PVA: Polyvinyl alcohol. 
 
CD30 and CD30L mRNA expression was determined in purified granulocytes of 
healthy donors by RT-PCR. Analysis of the PCR products showed clear CD30L but no CD30 
expression in granulocytes. As a control, RT-PCR of CD30 and CD30L mRNA expression 
was analyzed in CD30
+
 HL cell line L540. These cells in contrast, showed CD30 and no 
detectable CD30L expression (Fig. 24A). GAPDH served as a control housekeeping gene for 
both granulocytes and L540 cells. In line with the mRNA expression of CD30L in 
granulocytes, the cell surface protein expression was demonstrated by immunofluorescence. 
Cytospins of freshly purified granulocytes were stained with specific antibodies against CD30 
and CD30L. Isotype-matched antibodies served as controls. As determined by alexa-594 
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fluorochrome-labeled secondary antibody, red staining reveals surface expression of CD30L 
and in contrast, CD30 expression is completely absent. Hoechst 33342 stains, the multi-
lobulated nucleus in blue (Fig. 24B). 
To further confirm that granulocytes express CD30L, antibody competition 
experiments using CD30L protein were performed by FACS analysis. Freshly purified PMN 
were stained with monoclonal anti-human CD30L and corresponding isotype as primary 
antibodies followed by detection with its specific secondary antibody. For the competition 
experiments, primary antibodies were pre-incubated with purified CD30L protein (10 μg/ml) 
on ice and later the subsequent staining of granulocytes was performed using antibodies 
blocked with CD30L protein and untreated ones by flow cytometry. The surface expression 
of CD30L is clearly demonstrated and the staining of CD30L antibody to cells was 
considerably decreased, when pre-incubated with recombinant CD30L protein (Fig. 24C). 
This effect was not observed with the isotype-matched antibodies. Taken together, the 
analysis confirms the CD30L expression on granulocytes. 
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Figure 24: Expression of CD30L on granulocytes. (A) RT-PCR analysis of CD30L from granulocytes 
obtained from healthy donor CD30 from L540 cells. GAPDH was used as a control. (B) Granulocytes were 
stained with anti-CD30 antibody (left), isotype antibody (middle), or anti-CD30L antibody (right). The multi-
lobulated nucleus staining was stained with Hoechst 33342 (blue) and the CD30L-specific antibody detection 
determines the expression of CD30 ligand (red staining). (C) Antibody competition was performed to show the 
specific CD30 ligand expression on granulocytes. The background grey color indicates the staining of secondary 
antibody alone. The staining of CD30L was noted by the open histogram (pink) and could be blocked using 
CD30L protein (orange). The isotype control has a background staining but no specificity against CD30L 
protein (green and blue). 
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Different reports had evidenced that HRS cells secrete different chemokines and cytokines 
that are able to actively attract immune cells. For example, IL-5, CCL5, CCL22 and GM-CSF 
presumably attract eosinophils, CCL-5 attracts mast cells and IL-8 recruits neutrophils 
(Skinnider and Mak 2002). It has been well reviewed that these cytokines not only attract 
other cells but keep the integrity of HRS cell survival and proliferation (Aldinucci et al. 
2008). As mentioned earlier, the interesting characteristic feature of this micromilieu is the 
presence of sCD30, able to bind most of the CD30L
+
 immune cells in the environment.  
Making these points into context, the migration of granulocytes was tested upon stimulation 
with soluble CD30 using Time Lapse Video Microscopy (TLVM).  
An extra-cellular matrix glycoprotein, fibronectin (10 μg/ml) was coated on 24-well 
plates to facilitate the process of migration. Granulocytes were isolated from whole blood, 
plated in fibronectin-coated plates and stimulated with soluble supernatants derived from 
293T cells either transfected with vector alone (mock) or with full-length cDNA of CD30 
(LCD30). Granulocyte movements were measured by time-lapse microscopy under tissue 
culture conditions (37
o
C, 5% CO2) for 60 minutes. The cells were tracked down to observe 
their trajectory path for every minute of approximately 20-40 cells. The specific trajectory 
movements, when stimulated with sCD30 supernatants showed a significantly increased 
random migration of granulocytes in comparison with un-transfected and mock-transfected 
supernatants (Fig. 25). In addition, blocking the functional interaction of sCD30 and CD30L 
using anti-CD30 antibody (HeFi-1 at 3 μg/ml) inhibited the stimulation of sCD30-specific 
migration. On the other hand, migration was not inhibited when blocked with the 
corresponding isotype control. The data represents that sCD30 has an impact on granulocyte 
migration and might act as a chemo-attractant. Thus, the recruitment of inflammatory cells 
into the lymphoma microenvironment is also dependent on sCD30 and essential for the 
survival of HRS cells in HL. 
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Figure 25: Migration of granulocytes was measured using Time-Lapse Video Microscopy. Granulocyte 
migration was tested after stimulation with supernatants of untreated (neg), CD30-transfected (LCD30) and 
empty vector transfected (mock) 293T cells. All three stimulants were applied in the absence (Alone), or in 
presence of anti-CD30 antibody (HeFi-1) and control Ab (Isotype). Each dot shows the distance covered by an 
individual cell (path length in mm). Representative trajectories were randomly selected for 20-40 cells traced by 
using digitizer during 60 frames. Using Graph-pad prism software the statistical analysis was performed by 
student’s unpaired t- test for LCD30 (Alone) verses mock SN (Alone), LCD30 (Alone) versus LCD30 (HeFi-1) 
and LCD30 (HeFi-1) versus LCD30 (Isotype). ** P < 0.005, *** P < 0.0005. 
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To question further the stimulation of sCD30 on granulocyte migration, a directed migration 
assay was performed using trans-well system. This system is equipped with a 3 μm-pore size 
filter that fits into a 24-well plate. The soluble supernatants obtained from mock-transfected 
and CD30-transfected cells were diluted with medium and filled in the lower chamber and 
10
6 
granulocytes were placed in upper chamber. After incubation at 37
o
C for 50 minutes, the 
migration of cells to the lower chamber towards the sCD30 was determined to be better when 
compared towards the mock supernatant or un-transfected supernatant (Fig. 26). In line with 
the above migration results, this data further confirms that sCD30 not only stimulates the 
migration of granulocytes but also implies that the cells migrate towards the sCD30 gradient. 
                               
Figure 26: Trans-well assay. Directed migration was induced in granulocytes after stimulation with soluble 
CD30. The migrated granulocytes into the lower chamber were counted using trypan-blue when un-stimulated 
(Neg) or stimulated with soluble supernatants of LCD30 (LCD30) and vector-transfected supernatants (Mock). 
After 50 minutes incubation at 37
o
C, the migrating cells were counted and mean of at least three independent 
counts was represented. The significance was analyzed for LCD30 verses mock using unpaired t test. * P< 0.05. 
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HL is characterized with less than 1% malignant cells in the tumor tissue and 
abundant granulocytes in the reactive infiltrate. Elevated levels of IL-8 showed an association 
with B symptoms in Hodgkin patients. IL-8 expression in HL is largely confined to reactive 
cells and association with infiltration by neutrophils (Foss et al. 1996). It is well described 
that mast cells and granulocytes release IL-8 upon stimulation of immobilized CD30. Since 
HRS cells release sCD30, it has been an interesting point to check whether soluble CD30 
stimulates the IL-8 release from granulocytes. Similar to previous experiments, sCD30 
supernatant was obtained from 293T cells either un-transfected, or transfected with vector 
alone and CD30. Here, the cells were incubated with supernatants in serum free media for 
over-night at 37
o
C. The cell free supernatants were collected and were subjected to IL-8 
specific ELISA. As shown in Fig. 27, CD30 in soluble supernatant enhanced the IL-8 release 
from granulocytes in contrast to un-transfected or mock-transfected supernatants. The 
enhanced IL-8 release was blocked using anti-CD30 antibody (HeFi-1) at final concentration 
of 1 μg/ml. These results indicate that sCD30 also stimulates granulocytes to release IL-8 
resulting in an indirect effect on the angiogenesis of the tumor. 
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Figure 27: IL-8 secretion. Levels of IL-8 present in supernatants from granulocytes (5x10
5
/ 24 well) after 
overnight treatment with soluble CD30 (2000 units/ml) or control supernatants were used at equal volumes. 
Soluble supernatants were pre-incubated with anti-CD30 mAb (HeFi-1) for one hour at 37
o
C. Neg-cells alone, 
UT: un-transfected, Mock: vector transfected and LCD30: CD30 transfected. Minus (-) and plus (+) symbols 
indicate the absence and presence of antibody respectively. Error bars represent the standard deviation. 
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CD30 was first described in 1982 and recognized be selectively expressed on the 
malignant cells of Hodgkin lymphoma and a few activated lymphocytes. A few years 
later, in 1992, after molecular cloning, it was grouped as a member of the TNFR super 
family. Although expression and function of other family members were published soon 
after their first description, the physiological role of CD30 remained long time obscure. 
Even today, the function of CD30 is not fully understood. It is widely accepted that CD30 
is strongly expressed on activated B and T lymphocytes. In the present study we 
confirmed the expression of CD30 on activated NK cells as shown previously (Cambiaggi 
et al. 1993). To understand its physiological function, it is necessary to consider the 
expression of CD30 ligand too. Generally, the expression is weaker and less restricted in 
comparison to CD30. While CD30L expression is established on B cells and activated T 
cells as well as on monocytes/macrophages and mast cells (Smith et al. 1993; Armitage 
1994; Younes et al. 1996), the CD30L expression on other cells of the innate immune 
system needs confirmation. There is evidence about a highly restricted and regulated 
expression of CD30L on immune regulatory cells (Sun and Fink 2007). There are reports 
about an up-regulation of CD30L on myeloid and plasmacytoid dendritic cells in mice 
upon inflammation (Zeiser et al. 2007). Here, it is shown that human iDCs that were 
differentiated from monocytes show distinct CD30L expression, whereas it is down 
regulated upon maturation of iDCs. Similarly, in vitro-generated immature DCs, freshly 
isolated blood DCs, also express cell surface CD30 ligand. Polymorpho nuclear 
leukocytes, such as neutrophils, are cells that have also been suggested to express CD30L 
(Wiley). Although others challenged this finding, we clearly confirmed that CD30L is 
expressed on peripheral blood-derived granulocytes, both on the mRNA and on the 
protein level. Taken together, the following profile emerges: CD30 is selectively 
expressed on B, T and NK cells upon cell activation. CD30 ligand, by contrast, is broadly 
distributed on immune cells, such as activated T cells, granulocytes, mast cells as well as 
monocytes, macrophages and DCs.
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NK cells are a part of the innate immune system that is directly activated by cytokines and 
bacterial, viral or pathogen encounter. Since NK cells express CD30 only upon activation and 
highest CD30L expression in DCs was observed in immature status, we hypothesize that NK-
iDC interaction through CD30-CD30L might contribute to induce DC maturation. In this 
respect we showed in this work that i) cross-linking of CD30L caused signaling in iDCs. We 
found that stimulation of iDCs by CD30 receptor caused a transient cytoplasmic liberation of 
ROS followed by secretion of pro-inflammatory cytokines. ii) This DC stimulation used the 
MAP kinase pathway as demonstrated by selective pathway inhibitors. iii) We further showed 
that CD30L ligation caused DC maturation as demonstrated by measuring maturation marker 
at the cell surface. This effect was not only observed after direct stimulation of DCs with 
recombinant CD30 receptor but also in co-culture experiments using activated CD30
+
 NK 
cells. The cell-cell effect was CD30-CD30L-dependent because anti-CD30 antibodies caused 
significant reduction of DC maturation. Thus, we showed for the first time that DCs can 
maturate through reverse signaling, i.e. CD30 receptor is able to activate DCs through 
ligation of membrane-anchored CD30 ligand.  
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Reactive Oxygen Species (ROS) have long been considered as harmful by-products of 
intrinsic oxygen metabolism or cellular responses to hazardous stimuli. ROS has been 
implicated in various pathogenesis of various disorders, including cancers, aging, diabetes, 
atherosclerosis, chronic inflammation, HIV infection and injury (Droge 2002). But increasing 
evidence suggests that ROS serve as essential secondary messengers mediating cellular 
responses to many physiological stimuli (Reth 2002). ROS affect the maturation state, the 
production
 
and secretion of cytokines, and the antigen-presenting capacity
 
of DC (Alderman 
et al. 2002; Matsue et al. 2003; Vulcano et al. 2004; Tan et al. 2005). Like monocytes and 
neutrophils,
 
for example, DC are equipped with a membrane-localized electron
 
transport 
system, NADPH-oxidase, that reduces molecular oxygen
 
to superoxide anions at the expense 
of NADPH (Matsue et al. 2003; Elsen et al. 2004; Werling et al. 2004). Activation
 
of DC may 
thus initiate/include ROS-mediated autocrine/paracrine
 
regulatory functions. 
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The majority of studies of DC-generated ROS production have
 
been performed using 
in vitro-generated dendritic cells differentiated from human (Verhasselt et al. 1998; Rutault et 
al. 1999; Alderman et al. 2002; Kantengwa et al. 2003). Recently, quite a few data suggest 
that diverse receptors stimulate ROS production. These are not cytotoxic, but rather required 
for the MAPK family member activation, gene expression and/or cell proliferation (Lo and 
Cruz 1995; Sundaresan et al. 1995; Lo et al. 1996; Lee and Koretzky 1998; Sattler et al. 1999; 
Devadas et al. 2002). Wiley et al observed ROS generation in neutrophils upon cross linking 
CD30L with immobilized CD30 and activating the synthesis of cytokine release (Wiley et al. 
1996). In line with the above findings my results demonstrated that Mo-iDCs generate ROS 
(oxidative burst) upon activation with immobilized CD30. This oxidative burst was very 
rapid and a decrease immediately suggests that the ROS concentration was very low. Thus, 
the results support the current concept that ROS at low concentrations play physiological 
roles in cellular signaling via regulating the redox states of transcription factors and various 
enzymes involved in signal transduction (e.g. protein tyrosines phosphatases, receptor 
tyrosine kinases, mitogen-activated protein kinases (MAPK), protein kinase C) (Abate et al. 
1990; Droge 2002). 
The relationship of cytokine production and reactive oxygen species generated from 
DCs was known during antigen presentation (Matsue et al. 2003), whereas, this study aimed 
to examine the production of cytokines from iDCs upon CD30 stimulation. We showed that 
iDCs were able to release the proinflammatory cytokines TNF-alpha, IL-6, and IL-8. As a 
consequence of the oxidative stress, which is often associated with tissue injury, DCs could 
thus contribute to the local inflammatory response via their enhanced production of 
cytokines. The proinflammatory cytokines like IL-8 aids in the recruitment of immune cells 
whereas TNF-alpha and IL-6 synergizes in the activation of polymorph nuclear leukocytes 
(PMN). 
TNF-alpha has versatile functions in inflammatory responses particularly involved in 
systemic inflammation and stimulates the acute phase reaction. It appears to have profound 
effects on DC functions, as it contributes to their activation (Rieser et al. 1997), maturation 
(Brunner et al. 2000), and migration to, and accumulation within, draining lymph nodes 
(Cumberbatch and Kimber 1995). It significantly reduces IL-10 mediated inhibition of DC 
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development and function (Brossart et al. 2000). Recently, it has been shown that TNF-alpha 
trans-gene expressing DCs underwent cellular maturation and induced efficient CTL 
responses and subsequent anti-tumor immunity (Zhang et al. 2003). Interleukin-6 (IL-6) acts 
as both a proinflammatory and anti-inflammatory cytokine. It is well known that IL-6 is 
secreted by macrophages in response to specific microbial molecules, referred to as pathogen 
associated molecular patterns (PAMPs). Similar to TNF alpha, IL-6 also stimulates the acute 
phase reaction to generate inflammatory responses. These cytokines acts as autocrine 
regulators in inducing DC maturation and enhance the immuno-stimulatory capacity (Jonuleit 
et al. 1997). Hence, it would be possible that the secretion of TNF alpha and IL-6 from iDCs 
upon CD30 stimulation might contribute for the maturation of dendritic cells. 
In addition to TNF alpha and IL-6, IL-8 is another major pro-inflammatory cytokine 
that is released by CD30 stimulation from dendritic cells. Unlike TNF alpha and IL-6, IL-8 is 
not involved directly in activation of immune cells but rather acts a chemo-attractant to 
recruit granulocytes. IL-8 is a chemokine of the CXC family (CXCL8) whose major function 
is to attract and activate PMN particularly neutrophils to the site of inflammation (Baggiolini 
et al. 1997). On the other hand, enhanced production of this cytokine has been found in 
inflammatory disorders such as rheumatoid arthritis and ulcerative colitis, infectious diseases 
and inflammatory skin diseases. Furthermore, elevated levels of IL-8 have been also detected 
in sera of Hodgkin patients in about 30-50% of the cases. Thus it is tempting to speculate that 
IL-8 released from dendritic cells upon CD30 stimulation could possibly have a positive role 
in normal acute-inflammation, in contrast to the chronic inflammation where, elevated levels 
of IL-8 possibly have a negative effect. 
Production of lower concentrations of IL-10 from iDCs upon CD30 stimulation may 
be responsible for a proper control of the immune response during inflammation. It was 
demonstrated that IL-10 plays an important regulatory role on monocyte function and on DC 
maturation (de Waal Malefyt et al. 1991; Buelens et al. 1995). Dendritic cells secreting IL-10 
exhibit minimal or no stimulatory properties in primary MLRs and are markedly inhibitory to 
T cell proliferation induced by polyclonal activator (Ding and Shevach 1992). Thus, IL-10 
producing DCs are functionally and phenotypically inhibitory accessory cells and putatively 
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tolerogenic. However, so far it remains unclear, whether such lower concentrations reflect the 
efforts by the immune system to control inflammation. 
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MAPK signaling pathway is a highly conserved pathway that is involved in diverse cellular 
functions, including cell proliferation, cell differentiation, and apoptosis. The fundamental 
role of MAP kinases in innate immunity (inflammation) is closely related with in cytokine 
production by cells involved in the innate response (e.g. macrophages and dendritic cells). It 
was well documented that cytokine production is regulated mainly by three MAPK-pathways 
such as JNK, ERK, and p38 MAPKs. All share the common property of being activated via 
three- module phosphorylation cascade, which in turn allows them to phosphorylate a wide 
range of substrates, including other protein kinases, phospholipases and transcription factors 
(Chang and Karin 2001; Johnson and Lapadat 2002). Although there is some cross-talk and 
cell-type specificity, the JNK and p38 MAPK cascades are strongly activated by stress stimuli 
and inflammatory cytokines, where as ERK pathway is strongly activated by polypeptide 
growth factors through receptors for tyrosine kinase (Kyriakis and Avruch 2001). The 
findings of TNF-alpha ELISA show that three MAP kinases (p38, JNK and ERK) were 
involved in TNF-alpha production from CD30-stimulated iDCs. Specific inhibitors of three 
MAP kinases blocked the synthesis and release of TNF-alpha. This is in line with previous 
reports demonstrating that the TNF-alpha release upon MAP kinase inhibition was blocked in 
LPS and PMA-stimulated iDCs. From these results, it can be inferred or rather postulated that 
MAPK pathways play a major role in pro-inflammatory cytokine production by ROS 
generated from CD30-stimulated dendritic cells.
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During inflammation, recruitment, activation and maturation of almost all immune regulatory 
cells occur primarily at the inflammatory site with a strong burst of cytokines and chemokines 
from different cell types. Here it was shown, that maturation of iDCs is triggered by 
immobilized CD30-Ig (mimic of membrane anchored receptor) or upon co-culture with 
activated NK cells in a CD30-CD30L-dependent manner. NK-DC cross-talk leads to a 
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profound activation of both cell types, finally leading to the induction of signals for iDCs 
maturation. During this process it was well documented that engagement of NKp30 (NCR3) 
with DCs stimulates the release of pro-inflammatory cytokines (TNF-alpha and IFN-gamma) 
from NK cells, which contributes to the maturation of iDCs via paracrine mechanism. In 
contrast to these observations, this study in particular focused in explaining the effects of 
CD30 during iDC maturation with the release of TNF-alpha from iDCs itself describing an 
autocrine mechanism. Furthermore, inhibition of maturation process was not completely 
abolished when blocked with CD30-specific antibodies in NK-DC co-culture, bringing the 
fact that other receptors on NK cells like NKp30 or DNAM-1 were also involved. Thus, these 
results together infer that TNF-alpha-mediated maturation of iDCs in the bi-directional cross-
talk with NK cells could be induced by both autocrine and paracrine mechanisms. 
Moreover, consistent to the results obtained for the cytokine release (TNF-alpha and 
IL-6), immobilized CD30-Ig deletion constructs correspondingly induced iDC maturation. 
The degree of maturation is determined by the up-regulation of co-stimulatory molecules 
(CD80, CD83 and CD86). Previous reports observed that TNF-alpha or RANTES dependent 
DC maturation led to the aggregation of DCs (Sato et al. 1999; Enomoto et al. 2001). 
Differences in the maturation process within the CD30-Ig constructs directly correlated to the 
aggregation of dendritic cells. Cell clustering, which is a characteristic feature of mature DC 
cultures, probably results from the up-regulation of several surface molecules mediating cell-
cell interactions. Although the precise molecular mechanisms underlying DC aggregation is 
not clear, it was postulated that ICAM-1 (CD54), a cell adhesion molecule is involved in the 
formation of DC aggregates (H. Haegel-Kronenberger, unpublished data). 
 		
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As a consequence of CD30-dependent DC maturation, the study also describes the function of 
mature DCs in the formation of activated T-cell synapse and proliferation of naïve T-cells. It 
is known that maturation of DC is critical in inducing effective, naïve T cell priming and 
robust proliferation (Guermonprez et al. 2002). One of the major pre-requiste for a proper 
DC-T-cell contact is the expression of co-stimulatory and adhesion molecules on both cell-
types. Here it is demonstrated iDCs upon CD30L-engagement are able to form a proper 
immunological synapse (IS) with the clustering of CD3 receptor at the synapse. Interestingly, 
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unlike the formation of the IS with naïve T cells, CD30 derived mature DCs were more 
specific to activated T cells, probably correlating with a specific function for cytotoxic T- 
lymphocytes. In fact, this mechanism further supports that NK-DC cross talk play an 
important role in shaping the adaptive immune response. In addition to the function of T-cell 
polarization, CD30 derived mature DCs enhance the proliferation of either with CD3
+
 CD4
+
 
or CD3
+
 CD4
-
 T cells. 
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CD30 has been well documented to have a role in the pathogenesis of hematopoietic 
malignancies. CD30 is cleaved and the ectodomain (sCD30) is released in the 
microenvironment of the malignant cells. The tumor microenvironment in malignancies such 
as HL is characterized by an infiltration of many different types of immune cells including T 
cells, B cells, plasma cells, neutrophils, eosinophils and mast cells. Depending on the 
cytokines released different immune cells were recruited to the site of inflammatory tissue 
(Kuppers 2009). It is anticipated that the chronic inflammation in HL contributes to the tumor 
initiation, progression and survival of the malignant cells (HRS). Elevated sCD30 serum 
levels in HL patients correlate to the progression of the disease. Soluble CD30 binds to the 
CD30L
+
 cells and blocks the direct interaction with surface-expressed CD30 on HRS cells or 
ALCL, thereby inhibiting the biological effects of CD30L. The results shown in this study 
collectively uncover novel functions for sCD30 engaging CD30L on granulocytes that are 
usually present either in the HL microenvironment or in malignant lymphoma like ALCL, 
and also in RA. 
 The study shows that, human granulocytes express CD30L and HL cells release the 
soluble ectodomain of CD30 (sCD30). We found that sCD30 stimulates chemotaxis of 
granulocytes and elevated concentrations induced them to release IL-8. Therefore, it is 
conceivable that recruitment of inflammatory cells to the lymphoma microenvironment is due 
to the presence of sCD30. Previous studies have shown that some of the survival signals that 
are provided by inflammatory cells to the HRS cells are triggered by CD40 signaling by 
CD40L expressing rosetting T-cells and also by activation of TACI and BCMA through 
production of their ligand APRIL by neutrophils (Kuppers 2009). Similar to this fashion 
perhaps sCD30-CD30L interaction could also play a role in HRS survival. In contrast to the 
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data shown with soluble form, it has been previously described that immobilized CD30 
stimulate mast cells and neutrophils to secrete IL-8. Therefore, the content of IL-8 in the 
tumor microenvironment could be at elevated levels correlating to a role in the pathogenesis 
of HL (Trumper et al. 1994). However, sCD30-dependent release of IL-8 from granulocytes 
may affect angiogenesis positively and thus promote tumor progression. 
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The complex immune regulatory mechanisms by immune cells are modulated by various 
factors depending on the type of inflammation. Generally, inflammation is broadly classified 
as acute and chronic inflammation. Although, the mechanisms involved in acute and chronic 
inflammation differ a lot in inducing different immune responses, the effect of specific 
interactions under molecular level does not change. This study provides evidence for a crucial 
role of CD30-CD30L interaction in both the inflammatory responses. Based on the results I 
propose a model that early cell-cell dependent CD30-CD30L signaling is involved in acute 
inflammation whereas elevated levels of soluble sCD30 may contribute to chronic 
inflammation.  
 		
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Acute inflammation corresponds to infection of pathogens or viruses. NK cells play a major 
role in inducing primary immune responses, but they require specific activatory mechanisms.  
Until now, it has been suggested that the early phases of an inflammatory response involves 
the activation of toll-like receptors (TLRs) by pathogen-associated molecular patterns 
(PAMPs) and result in NK-DC interaction. But recent reports strongly suggest that NK cells 
need to be primed before their activation to dendritic cells, and this priming is mediated by 
various cytokines like IL-4, IFN- or IL-18 released from other innate cells like eosinophils, 
neutrophils, monocytes and mast cells. This could be termed as “primary activation of NK 
cells”. This primary activation results in expression of CD30 on NK cells. Moreover, it has 
been shown that CD30 expression is sustained in presence of IL-4. Thus we could 
hypothesize that CD30-expressing NK cells might then interact and activate CD30L+ 
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dendritic cells to induce pro-inflammatory responses leading to the maturation of dendritic 
cells and finally elicit the T-cell mediated responses. Thus mostly, the function of CD30-
CD30L interaction in acute inflammation is dependent on cell-cell contact (Fig. 28). 
 			
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Prolonged inflammation, known as chronic inflammation, leads to a progressive shift in the 
type of cells which are present at the site of inflammation and is characterized by 
simultaneous destruction and healing of the tissue from the inflammatory process. The best 
known examples are the lymphomas or autoimmune disorders. However, chronic 
inflammation is generally linked to tumor initiation and progression. The chronic lymphomas 
and in particular HL are best characterized by the recruitment of large number of 
inflammatory cells and elevated levels of CD30 in its soluble form (sCD30). In contrast to the 
acute inflammation the immune effector cells (NK or T cells) were suppressed or absent. In 
this study it was shown that sCD30 has a direct function on migration of granulocytes and 
release of IL-8. Thus it is tempting to speculate that sCD30 mediated directed migration, 
results in the accumulation of inflammatory granulocytes in the Hodgkin tissue. Their release 
of IL-8 is probably responsible for tumor maintenance and progression (Fig. 28). The release 
of IL-10 from DCs upon stimulation with sCD30 may act as an anti-inflammatory cytokine 
that provide immune-tolerance in the tumor microenvironment. This could result in the 
suppression of T or NK cell function. 
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Figure 28: Hypothetical Model of CD30-CD30L function in inflammation 
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